Ludwig Kappos

Q: What Schools Are Affiliated With Ludwig Kappos

Ludwig Kappos is affiliated with the following schools: University of Basel, Queen Mary University of London

Ludwig Kappos's AcademicInfluence.com Rankings

Ludwig Kappos

Philosophy

#3554

World Rank

#5716

Historical Rank

Logic

#1236

World Rank

#1930

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Ludwig Kappos's Degrees

Doctorate Medicine University of Basel

Why Is Ludwig Kappos Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ludwig Kappos's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria (2011) (8941)
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” (2005) (5003)
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (2017) (3544)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. (2006) (2970)
Defining the clinical course of multiple sclerosis (2014) (2372)
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. (2010) (2329)
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. (2010) (2040)
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. (2012) (1465)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis (2017) (1170)
Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis (2017) (1107)
Neurofilaments as biomarkers in neurological disorders (2018) (939)
Oral fingolimod (FTY720) for relapsing multiple sclerosis. (2006) (854)
Randomized trial of oral teriflunomide for relapsing multiple sclerosis. (2011) (845)
Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis (1998) (801)
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci (2009) (799)
Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis (2017) (668)
Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis (2017) (668)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial (2014) (647)
MRI CRITERIA FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS: MAGNIMS CONSENSUS GUIDELINES (2016) (631)
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial (2011) (625)
Differential diagnosis of suspected multiple sclerosis: a consensus approach (2008) (624)
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes (2006) (576)
PRISMS-4: Long-term efficacy of interferon-&bgr;-1a in relapsing MS (2001) (567)
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study (2018) (559)
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study (2007) (503)
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial (2000) (499)
Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis (1999) (484)
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. (2009) (464)
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study (2008) (449)
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial (2014) (448)
Vitamin D as an early predictor of multiple sclerosis activity and progression. (2014) (428)
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients (2015) (403)
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis (2009) (400)
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. (1991) (396)
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring (2007) (391)
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. (2019) (379)
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial (2009) (368)
Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases (2013) (365)
Placebo-controlled trial of oral laquinimod for multiple sclerosis. (2012) (350)
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process (2015) (346)
Myelin basic protein‐specific T lymphocyte lines from MS patients and healthy individuals (1990) (340)
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial (2016) (331)
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis (2008) (321)
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis (2018) (319)
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS (2007) (317)
Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. (1990) (307)
Correlations between changes in disability and T2‐weighted brain MRI activity in multiple sclerosis (1995) (299)
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial (2014) (298)
Self glycolipids as T‐cell autoantigens (1999) (297)
Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis (2018) (287)
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS (2006) (273)
Secondary progressive multiple sclerosis: current knowledge and future challenges (2006) (272)
Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. (1998) (270)
Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis (2001) (269)
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response (2019) (267)
The incidence and significance of anti-natalizumab antibodies (2007) (260)
MRI criteria for MS in patients with clinically isolated syndromes (2010) (256)
Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial (2014) (255)
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study (2015) (255)
Copeptin: A novel, independent prognostic marker in patients with ischemic stroke (2009) (255)
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial (2014) (254)
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab (2012) (239)
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. (2015) (237)
Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene. (2010) (236)
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study (2011) (224)
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis (2018) (224)
Ofatumumab versus Teriflunomide in Multiple Sclerosis. (2020) (220)
Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis (2015) (220)
Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. (1993) (217)
A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS (2002) (216)
Interferon beta-1b in secondary progressive MS (2004) (207)
The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. (2000) (203)
Oral fingolimod (FTY720) in multiple sclerosis (2009) (202)
Altered expression of miR‐17‐5p in CD4+ lymphocytes of relapsing–remitting multiple sclerosis patients (2010) (202)
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study (2013) (194)
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial (2012) (194)
MRI T2 lesion burden in multiple sclerosis (2006) (193)
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy (2011) (193)
Rapamycin Attenuates the Progression of Tau Pathology in P301S Tau Transgenic Mice (2013) (192)
Health‐related quality of life in multiple sclerosis: effects of natalizumab (2007) (190)
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis (2010) (183)
The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. (2001) (181)
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability (2011) (180)
Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis (2009) (175)
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis (2011) (164)
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results (2014) (160)
MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis (2006) (156)
Analysis of Impairment Related Functional Architecture in MS Patients during Performance of Different Attention Tasks (2003) (156)
The αβ T Cell Response to Self-Glycolipids Shows a Novel Mechanism of CD1b Loading and a Requirement for Complex Oligosaccharides (2000) (151)
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study (2012) (149)
Hematopoietic stem cell transplantation for multiple sclerosis (2002) (148)
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis (2015) (146)
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring (2007) (146)
Visual and motor evoked potentials in the course of multiple sclerosis. (2001) (145)
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results (2010) (145)
Lack of association between antimyelin antibodies and progression to multiple sclerosis. (2007) (141)
Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. (2015) (141)
Age-Dependent B Cell Autoimmunity to a Myelin Surface Antigen in Pediatric Multiple Sclerosis1 (2009) (140)
Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype (2015) (139)
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL (2009) (139)
Final analysis of the European multicenter trial on IFNβ-1b in secondary-progressive MS (2001) (138)
Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients. (2013) (138)
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study (2015) (138)
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials (2020) (137)
Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. (2015) (136)
Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome (2014) (135)
Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. (2002) (133)
Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. (2015) (133)
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study (2016) (130)
Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b (2003) (129)
Can the Expanded Disability Status Scale be assessed by telephone? (2003) (129)
Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis (2019) (128)
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis (2007) (127)
Working memory training in patients with multiple sclerosis - comparison of two different training schedules. (2009) (126)
Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis (2015) (125)
Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis (2011) (125)
Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review) (2008) (124)
Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis (2011) (124)
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis (2014) (124)
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome (2015) (123)
Black holes in multiple sclerosis: definition, evolution, and clinical correlations (2009) (122)
A comparative study of CSF neurofilament light and heavy chain protein in MS (2013) (120)
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis (2015) (119)
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage (2013) (118)
Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study (2014) (118)
Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study (2013) (118)
Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis (2014) (118)
Natalizumab: Targeting α4-Integrins in Multiple Sclerosis (2007) (116)
Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. (2005) (116)
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy (2014) (115)
Nonconventional MRI and microstructural cerebral changes in multiple sclerosis (2015) (113)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial (2019) (113)
Long-term effects of fingolimod in multiple sclerosis (2015) (113)
MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice (2020) (113)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial (2019) (112)
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (2021) (110)
Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients (2008) (108)
Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects. (2012) (108)
MR Imaging in Multiple Sclerosis: Review and Recommendations for Current Practice (2010) (108)
The current role of MRI in differentiating multiple sclerosis from its imaging mimics (2018) (107)
Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis (2013) (107)
Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings. (2014) (106)
Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. (2019) (105)
Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks (2010) (105)
Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration (2014) (103)
Neutralizing antibodies and efficacy of interferon β-1a (2005) (102)
Fatigue in multiple sclerosis: relation to depression, physical impairment, personality and action control (2007) (101)
Multiple sclerosis as a generalized CNS disease—comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS (2004) (101)
T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. (2001) (101)
Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: Application of an extended blood‐brain barrier leakage correction (2000) (100)
Cyclosporine versus azathioprine in the long‐term treatment of multiple sclerosis—results of the german multicenter study (1988) (100)
Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis (2018) (98)
Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. (2012) (98)
MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis (2015) (97)
The 11-year long-term follow-up study from the randomized BENEFIT CIS trial (2016) (97)
Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis (2019) (97)
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis (2009) (97)
Prognostic Value of Copeptin: One-Year Outcome in Patients With Acute Stroke (2010) (95)
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL (2009) (94)
Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis — A longitudinal voxel-based morphometry study (2009) (93)
Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. (2000) (93)
Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions (2018) (92)
Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. (2019) (92)
Assessing response to interferon-β in a multicenter dataset of patients with MS (2016) (89)
Extraocular Blood Flow and Endothelin-1 Plasma Levels in Patients with Multiple Sclerosis (2003) (87)
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS (2016) (87)
Learning from Nature: Pregnancy Changes the Expression of Inflammation-Related Genes in Patients with Multiple Sclerosis (2010) (86)
Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. (2016) (85)
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis (2013) (84)
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT (2013) (84)
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study (2022) (83)
Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience (2015) (83)
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi‐centre fMRI study (2008) (83)
Mannose-Binding Lectin Deficiency Is Associated With Smaller Infarction Size and Favorable Outcome in Ischemic Stroke Patients (2011) (82)
The effect of interferon β-1b on quantities derived from MT MRI in secondary progressive MS (2003) (82)
A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein (2010) (81)
Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders (2019) (81)
Biplanar MRI for the assessment of the spinal cord in multiple sclerosis (2012) (81)
Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation (2000) (80)
Measuring and Validating the Levels of Brain-Derived Neurotrophic Factor in Human Serum (2018) (80)
Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis (2012) (80)
MS disease activity in RESTORE (2014) (80)
Magnetic resonance imaging outcomes from a phase III trial of teriflunomide (2013) (79)
The hippocampus in multiple sclerosis (2018) (79)
Cerebellar Abnormalities Contribute to Disability Including Cognitive Impairment in Multiple Sclerosis (2014) (78)
Teriflunomide added to interferon-&bgr; in relapsing multiple sclerosis: A randomized phase II trial (2012) (77)
The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients (2014) (77)
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. (2021) (76)
Neurofilament light chain level is a weak risk factor for the development of MS (2016) (75)
The current role of MRI in differentiating multiple sclerosis from its imaging mimics (2018) (74)
Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b (2008) (74)
Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15 (2015) (74)
Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS (2011) (74)
Escalating immunotherapy of multiple sclerosis--new aspects and practical application. (2004) (73)
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. (2016) (72)
Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials (1997) (72)
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP) (2020) (71)
Long-term safety and efficacy of teriflunomide (2016) (71)
First-dose effects of fingolimod: Pooled safety data from three phase 3 studies. (2014) (71)
MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials (2012) (71)
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS (2012) (71)
Endonasal Surgery for Contact Point Headaches: A 10‐Year Longitudinal Study (2003) (71)
Predictors of relapse rate in MS clinical trials (2005) (70)
Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke. (2010) (69)
Sodium intake and multiple sclerosis activity and progression in BENEFIT (2017) (69)
Blood neurofilament light levels segregate treatment effects in multiple sclerosis (2020) (68)
Unraveling treatment response in multiple sclerosis (2018) (68)
The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. (2000) (66)
Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data (2011) (66)
The effect of IFNβ-1b on the evolution of enhancing lesions in secondary progressive MS (2001) (66)
Clinical–MRI correlations in a European trial of interferon beta-1b in secondary progressive MS (2001) (66)
Advances in oral immunomodulating therapies in relapsing multiple sclerosis (2020) (66)
Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. (2019) (65)
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study (2014) (65)
Neutralizing antibodies against IFN-β in multiple sclerosis: antagonization of IFN-β mediated suppression of MMPs (2004) (65)
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study (2012) (65)
The Genetic Association of Variants in CD6, TNFRSF1A and IRF8 to Multiple Sclerosis: A Multicenter Case-Control Study (2011) (64)
Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. (2014) (64)
Proton MRS of Gadolinium‐enhancing MS Plaques and Metabolic Changes in Normal‐Appearing White Matter (1995) (64)
Balance control in multiple sclerosis: correlations of trunk sway during stance and gait tests with disease severity. (2013) (63)
Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis (2012) (63)
Abnormal connectivity of the sensorimotor network in patients with MS: A multicenter fMRI study (2009) (63)
Multiple sclerosis registries in Europe – results of a systematic survey (2014) (62)
Switching from natalizumab to fingolimod (2015) (61)
Anterior pituitary axis hormones and outcome in acute ischaemic stroke (2011) (61)
Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study (2017) (60)
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial (2020) (60)
Fingolimod for Multiple Sclerosis: Mechanism of Action, Clinical Outcomes, and Future Directions (2011) (60)
T-cell response against varicella-zoster virus in fingolimod-treated MS patients (2013) (60)
Comparative efficacy of switching to natalizumab in active multiple sclerosis (2015) (60)
Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF (2007) (60)
Evoked potentials for evaluation of multiple sclerosis (2001) (60)
Stress hormones predict cerebrovascular re-events after transient ischemic attacks (2011) (60)
Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: The DEFINE study (2014) (59)
Five years of ocrelizumab in relapsing multiple sclerosis (2020) (59)
Effect of dimethyl fumarate on lymphocytes in RRMS (2019) (59)
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis (2019) (58)
Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition (2008) (58)
Combined evoked potentials as markers and predictors of disability in early multiple sclerosis (2012) (58)
Neurofilament light levels are associated with long-term outcomes in multiple sclerosis (2019) (58)
Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study (2017) (57)
A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients (2015) (57)
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the DEFINE study (2013) (57)
Teriflunomide slows BVL in relapsing MS (2017) (57)
Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations (2018) (57)
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients (2017) (57)
Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis. (2018) (57)
Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study (2011) (55)
Prediction of long-term disability in multiple sclerosis (2012) (55)
Reproducibility of fMRI in the clinical setting: Implications for trial designs (2008) (55)
Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study (2011) (53)
MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b (2003) (53)
Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions. (1997) (52)
Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial (2016) (52)
Evidence for acute neurotoxicity after chemotherapy (2010) (52)
Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsing‐remitting multiple sclerosis (2010) (52)
Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4+ T Cells of Patients with Relapsing-Remitting Multiple Sclerosis (2014) (51)
Therapy-induced plasticity of cognitive functions in MS patients: Insights from fMRI (2006) (51)
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. (2007) (51)
Relation between functional brain imaging, cognitive impairment and cognitive rehabilitation in patients with multiple sclerosis (2007) (51)
Molecular mechanism underlying the impact of vitamin D on disease activity of MS (2014) (50)
Multivariate pattern classification of gray matter pathology in multiple sclerosis (2012) (50)
The effect of interferon beta-1 b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis (2000) (50)
On the origin of Neurostatus. (2015) (50)
A comparative analysis of Patient-Reported Expanded Disability Status Scale tools (2015) (49)
Effect of delayed‐release dimethyl fumarate on no evidence of disease activity in relapsing–remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies (2017) (49)
Balancing the Th1/Th2 concept in multiple sclerosis. (1998) (49)
Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis (2019) (48)
Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials (2005) (48)
A CLINICAL COMPARISON OF SUMATRIPTAN NASAL SPRAY AND DIHYDROERGOTAMINE NASAL SPRAY IN THE ACUTE TREATMENT OF MIGRAINE (2000) (48)
Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years (2014) (48)
Short-term adaptation to a simple motor task: A physiological process preserved in multiple sclerosis (2009) (48)
Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis (2021) (48)
Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis. (2003) (47)
Determinants of iron accumulation in deep grey matter of multiple sclerosis patients (2014) (47)
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT (2015) (47)
Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis (2000) (47)
Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019 (2020) (46)
Neutralising antibodies to interferon β during the treatment of multiple sclerosis (2003) (46)
Oculopharyngeal muscular dystrophy - an under-diagnosed disorder? (2005) (46)
Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. (2016) (44)
Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis (2017) (44)
Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis (2018) (43)
BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis (2011) (43)
Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis (2010) (43)
Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study (2003) (43)
Antigen‐specific adaptive immune responses in fingolimod‐treated multiple sclerosis patients (2011) (43)
European validation of a standardized clinical description of multiple sclerosis (2004) (43)
Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial (2016) (42)
Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis (2020) (42)
Mental health problems in children of somatically ill parents, e.g. multiple sclerosis (2007) (42)
Cocapture of cognate and bystander antigens can activate autoreactive B cells (2017) (42)
Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results (2019) (42)
White matter lesion filling improves the accuracy of cortical thickness measurements in multiple sclerosis patients: a longitudinal study (2014) (42)
Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis (2006) (42)
Infusion-related hypersensitivity reactions during natalizumab treatment (2006) (42)
Neutralising antibodies to interferon β in multiple sclerosis (2007) (42)
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis (2019) (42)
Preferential spinal cord volume loss in primary progressive multiple sclerosis (2019) (41)
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus (2021) (41)
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a (2018) (41)
Siponimod and Cognition in Secondary Progressive Multiple Sclerosis (2020) (41)
Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis (2018) (41)
Longitudinal gray matter changes in multiple sclerosis—Differential scanner and overall disease‐related effects (2012) (41)
Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis (2021) (40)
Blood neurofilament light as a potential endpoint in Phase 2 studies in MS (2019) (40)
Spinal cord volume loss (2018) (40)
Interferon β-1b and glatiramer acetate effects on permanent black hole evolution (2011) (40)
T cell receptor γδ repertoire is skewed in cerebrospinal fluid of multiple sclerosis patients: molecular and functional analyses of antigen‐reactive γδ clones (1995) (40)
Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE (2020) (39)
Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial (2012) (39)
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course (2013) (39)
Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use (2013) (39)
Label‐fusion‐segmentation and deformation‐based shape analysis of deep gray matter in multiple sclerosis: The impact of thalamic subnuclei on disability (2014) (39)
Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis (2014) (39)
Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization (2005) (38)
A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients — A twelve month follow-up (2015) (38)
Interferon β-1b–neutralizing antibodies 5 years after clinically isolated syndrome (2011) (38)
The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options (2016) (38)
Combined acute disseminated encephalomyelitis and acute motor axonal neuropathy after vaccination for hepatitis A and infection with Campylobacter jejuni (1999) (38)
MiR-126: a novel route for natalizumab action? (2014) (38)
Myelin and axon pathology in multiple sclerosis assessed by myelin water and multi-shell diffusion imaging (2021) (38)
Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study (2014) (38)
Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. (2009) (37)
Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis (2015) (37)
Interferon β-1a in relapsing multiple sclerosis: four-year extension of the European IFNβ-1a Dose-C omparison Study (2004) (37)
Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. (2004) (37)
Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial (2017) (36)
Altered functional adaptation to attention and working memory tasks with increasing complexity in relapsing‐remitting multiple sclerosis patients (2011) (36)
Interleukin 17F level and interferon β response in patients with multiple sclerosis. (2013) (36)
Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies. (2014) (36)
Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis (2010) (36)
Quantifying Progression of Multiple Sclerosis via Classification of Depth Videos (2014) (36)
Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis (2012) (36)
Preserved Antigen-Specific Immune Response in Patients with Multiple Sclerosis Responding to IFNβ-Therapy (2013) (35)
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial (2012) (35)
The association between olfactory bulb volume, cognitive dysfunction, physical disability and depression in multiple sclerosis (2016) (35)
Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis (2021) (35)
Neuropsychological dysfunction, depression, physical disability, and coping processes in families with a parent affected by multiple sclerosis (2008) (34)
Screening for balance disorders in mildly affected multiple sclerosis patients (2012) (34)
Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis. (2014) (34)
Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS (2017) (34)
Effect of immunomodulatory medication on regional gray matter loss in relapsing–remitting multiple sclerosis—A longitudinal MRI study (2010) (33)
Spatio-temporal Segmentation of Active Multiple Sclerosis Lesions in Serial MRI Data (2001) (33)
A knowledge-driven interaction analysis reveals potential neurodegenerative mechanism of multiple sclerosis susceptibility (2010) (33)
Evaluation of a new approach for semi-automatic segmentation of the cerebellum in patients with multiple sclerosis (2012) (33)
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis (2016) (32)
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study (2018) (32)
Swallowing abnormalities in multiple sclerosis: correlation between videofluoroscopy and subjective symptoms (2002) (32)
Hereditary defect of cobalamin metabolism (homocystinuria and methylmalonic aciduria) of juvenile onset. (1996) (32)
[Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment]. (2000) (32)
3D GRASE arterial spin labelling reveals an inverse correlation of cortical perfusion with the white matter lesion volume in MS (2012) (32)
Survey of diagnostic and treatment practices for multiple sclerosis in Europe (2017) (32)
Fingolimod effect on brain volume loss independently contributes to its effect on disability (2015) (32)
Progression in disability and regional grey matter atrophy in relapsing–remitting multiple sclerosis (2014) (31)
Power estimation for non-standardized multisite studies (2016) (31)
Comparative efficacy of first-line natalizumab vs IFN-&bgr; or glatiramer acetate in relapsing MS (2016) (31)
Ethics of placebo-controlled clinical trials in multiple sclerosis (2008) (31)
Genetic associations with brain cortical thickness in multiple sclerosis (2015) (31)
Interleukin 15 stimulates production of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by human peripheral blood mononuclear cells. (2001) (30)
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. (2007) (30)
Gender-Specific Differences in the Process of Coping in Families with a Parent Affected by a Chronic Somatic Disease (e.g. Multiple Sclerosis) (2001) (30)
Histone deacetylase gene variants predict brain volume changes in multiple sclerosis (2013) (30)
Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study (2016) (30)
Effect of drugs in secondary disease progression in patients with multiple sclerosis (2004) (29)
Fluid biomarker and electrophysiological outcome measures for progressive MS trials (2017) (29)
Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis (2019) (29)
A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence (2019) (29)
Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO (2020) (29)
Gelatinase B [matrix metalloproteinase (MMP)‐9] and collagenases (MMP‐8/‐13) are upregulated in cerebrospinal fluid during aseptic and bacterial meningitis in children (2006) (29)
Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life - A post hoc analysis of the TEMSO and TOWER studies. (2016) (28)
Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study. (2004) (28)
Retraining attention in MS (2006) (27)
Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis (2015) (27)
The distribution of magnetic resonance imaging response to interferonβ–1b in multiple sclerosis (2005) (27)
Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies (2007) (27)
Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis (2020) (27)
The challenge of follow-on biologics for treatment of multiple sclerosis (2009) (27)
Monitoring multiple sclerosis by multimodal evoked potentials: Numerically versus ordinally scaled scoring systems (2016) (26)
Natalizumab-induced POU2AF1/Spi-B upregulation (2016) (26)
Vitamin D, smoking, EBV, and long-term cognitive performance in MS (2020) (26)
Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial. (1995) (26)
Relapses in patients treated with fingolimod after previous exposure to natalizumab (2015) (26)
Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review. (2020) (26)
Atorvastatin Added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial (2014) (25)
Damage of the lateral geniculate nucleus in MS (2019) (25)
Case-Based fMRI Analysis after Cognitive Rehabilitation in MS: A Novel Approach (2015) (25)
Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis (2017) (25)
Cognitive rehabilitation of working memory in juvenile multiple sclerosis-effects on cognitive functioning, functional MRI and network related connectivity. (2015) (25)
Disease Variables and Depression Affecting the Process of Coping in Families with a Somatically Ill Parent (2007) (24)
Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life. (2001) (24)
Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes (2013) (23)
Dimethyl fumarate for multiple sclerosis (2010) (23)
MRI study of Baló's concentric sclerosis before and after immunosuppressive therapy (1989) (23)
Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus. (2018) (23)
Spatiotemporal distribution of white matter lesions in relapsing–remitting and secondary progressive multiple sclerosis (2012) (23)
Lack of Association Between Antiphospholipid Antibodies and Migraine (1993) (22)
Pattern of macular thickness changes measured by ocular coherence tomography in patients with multiple sclerosis. (2008) (22)
Efficacy and safety of ocrelizumab in relapsing multiple sclerosis: Results of the IFN-β-1a-controlled, double-blind, Phase III OPERA I and II studies (2016) (22)
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE (2015) (22)
Anti-interferon-beta neutralising activity is not entirely mediated by antibodies. (2007) (22)
Teriflunomide for oral therapy in multiple sclerosis (2012) (22)
A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis (2016) (22)
Facing privacy in neuroimaging: removing facial features degrades performance of image analysis methods (2019) (22)
Natalizumab Therapy for Multiple Sclerosis (2013) (22)
Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST) (2014) (22)
α4-integrin receptor desaturation and disease activity return after natalizumab cessation (2017) (22)
Myelin-specific T lymphocytes in multiple sclerosis patients and healthy individuals (1988) (22)
Multicenter R2* mapping in the healthy brain (2014) (21)
Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis (2015) (21)
Glutamate gene polymorphisms predict brain volumes in multiple sclerosis (2013) (21)
Long-term prognostic value of longitudinal measurements of blood neurofilament levels (2020) (21)
[Cerebral and spinal MRI examination in patients with clinically isolated syndrome and definite multiple sclerosis]. (2008) (21)
Usability and Acceptability of ASSESS MS: Assessment of Motor Dysfunction in Multiple Sclerosis Using Depth-Sensing Computer Vision (2015) (21)
MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry (2018) (21)
Interferon beta-1b treatment does not induce autoantibodies (2005) (20)
Gender-specific differences coping with chronic somatic disease (e.g. Multiple Sclerosis) (2000) (20)
Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study (2017) (20)
Multiple Sclerosis and Antibodies against KIR4.1. (2016) (20)
Longitudinal patterns of cortical thinning in multiple sclerosis (2020) (20)
Genomics and proteomics: role in the management of multiple sclerosis (2005) (20)
Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis (2014) (20)
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome (2014) (20)
A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression (2018) (20)
Reconsidering clinical outcomes in Multiple Sclerosis: Relapses, impairment, disability and beyond (2008) (19)
Anti-interferon-β neutralising activity is not entirely mediated by antibodies (2007) (19)
Interferon-beta antibodies: implications for the treatment of MS (2003) (19)
SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts (2018) (19)
MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome (2009) (19)
Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study (2014) (19)
Indication for Psychotherapy in Offspring of a Parent Affected by a Chronic Somatic Disease (e.g. Multiple Sclerosis) (2005) (19)
Teriflunomide Efficacy and Safety in Patients with Relapsing Multiple Sclerosis: Results from TOWER, a Second, Pivotal, Phase 3 Placebo-Controlled Study (S01.004) (2013) (19)
Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study (2018) (19)
Gender effects on intramuscular interferon beta-1a in relapsing–remitting multiple sclerosis: analysis of 1406 patients (2011) (18)
Monitoring of radiologic disease activity by serum neurofilaments in MS (2020) (18)
Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial (2021) (18)
No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study (2017) (18)
Clinical Correlations of Brain Lesion Location in Multiple Sclerosis: Voxel-Based Analysis of a Large Clinical Trial Dataset (2018) (18)
Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: Design of the phase 3 EXPAND trial (2013) (18)
Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide (2019) (18)
Long-term safety of fingolimod: Interim evaluation of data from the longterms trial (2014) (18)
MAGNETIC RESONANCE IMAGING AND EARLY DIAGNOSIS OF MULTIPLE SCLEROSIS (1988) (17)
Natalizumab-induced POU 2 AF 1 / Spi-B upregulation A possible route for PML development (17)
Efficacy and Safety of Fingolimod in an Unselected Patient Population (2016) (17)
A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis (2005) (17)
Siponimod Reduces Neurofilament Light Chain Blood Levels in Secondary Progressive Multiple Sclerosis Patients (S8.006) (2018) (17)
Rigidity of retinal vessels in patients with multiple sclerosis. (2009) (17)
Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results (2021) (17)
The multiple sclerosis PRISMS study: Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis (1997) (17)
The use of magnetic resonance imaging in multiple sclerosis treatment trials: power calculations for annual lesion load measurement (2000) (17)
Transcriptional profiling of multiple sclerosis: towards improved diagnosis and treatment (2006) (16)
Accurate, rapid and reliable, fully automated MRI brainstem segmentation for application in multiple sclerosis and neurodegenerative diseases (2019) (16)
Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy (2016) (16)
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. (2018) (16)
Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy (2018) (16)
Evaluation of soluble HLA-G as a biomarker for multiple sclerosis (2011) (16)
Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future? (2004) (16)
Pooled historical MRI data as a basis for research in multiple sclerosis - a statistical evaluation (2007) (16)
Evolution of MS lesions to black holes under DNA vaccine treatment (2012) (16)
Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis - outline of a double-blind randomized, placebo-controlled trial (1997) (16)
Competing interests in multiple sclerosis research (2003) (16)
Immune-mediated neuropathies: etiology and pathogenic relationship to aging processes (2003) (16)
Fatal vascular leak syndrome with extensive hemorrhage, peripheral neuropathy and reactive erythrophagocytosis: an unusual complication of recombinant IL-3 therapy. (1996) (16)
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS (2015) (16)
Learning ability correlates with brain atrophy and disability progression in RRMS (2018) (16)
Evaluating the potential benefit of interferon treatment in multiple sclerosis. (2012) (16)
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS). (2014) (16)
Optimizing treatment initiation: Effects of a patient education program about fingolimod treatment on knowledge, self-efficacy and patient satisfaction. (2015) (15)
Prognostic factors for long-term outcomes in relapsing–remitting multiple sclerosis (2016) (15)
Development of multiple sclerosis in patient on long-term sulfasalazine (1990) (15)
Delay from treatment start to full effect of immunotherapies for multiple sclerosis. (2020) (15)
Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials. (2017) (15)
Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis (2015) (15)
Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis (2005) (15)
Qualitative and quantitative analysis of antibody response against IFNβ in patients with multiple sclerosis (2006) (15)
Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis (2015) (15)
Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon beta-1a-Controlled OPERA I and OPERA II Studies (PL02.004) (2016) (15)
Progression of gray matter atrophy and its association with white matter lesions in relapsing–remitting multiple sclerosis (2009) (14)
Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study (2010) (14)
Week 144 Results of a Phase II, Randomized, Multicenter Trial Assessing the Safety and Efficacy of Ocrelizumab in Patients with Relapsing–Remitting Multiple Sclerosis (RRMS) (S31.004) (2013) (14)
Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study (2006) (14)
PARP-1 deregulation in multiple sclerosis (2019) (14)
Non-communicating syringomyelia: a feature of spinal cord involvement in multiple sclerosis. (2008) (14)
Teriflunomide Increases the Proportion of Patients Free from Disease Activity in the TEMSO Phase III Study (PD5.007) (2012) (14)
Presence of SARS-CoV-2 Transcripts in the Choroid Plexus of MS and Non-MS Patients With COVID-19 (2021) (14)
BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis (2006) (14)
Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial) (2016) (14)
P 2 Effect of ocrelizumab on humoral immunity markers in the phase iii, double-blind, double-dummy, IFN β -1a–controlled OPERA I and OPERA II studies (2017) (14)
Association of Vitamin D LevelsWithMultiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1 b (2015) (14)
Clinical results from AFFIRM: A randomized, double-blind, placebo-controlled, multicenter trial to determine the efficacy and safety of natalizumab in patients with relapsing multiple sclerosis (MS) (2005) (14)
Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study (2014) (14)
Cervical dystonia as first manifestation of multiple sclerosis (2004) (13)
Multiple Sclerosis : Tissue Destruction and Repair (2001) (13)
Long-Term Efficacy and Safety of Fingolimod (FTY720) in Relapsing-Remitting Multiple Sclerosis (RRMS): Results from the Extension of the Phase III FREEDOMS Study (S41.004) (2012) (13)
Multiple sclerosis trials (1999) (13)
Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS (2021) (13)
Antigen Extraction and B Cell Activation Enable Identification of Rare Membrane Antigen Specific Human B Cells (2019) (13)
BG-12 (Dimethyl Fumarate) and Pregnancy: Preclinical and Clinical Data from the Clinical Development Program (P02.129) (2013) (13)
Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis (2012) (13)
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis (2020) (13)
Improved Characterization of Visual Evoked Potentials in Multiple Sclerosis by Topographic Analysis (2013) (12)
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years (2022) (12)
MRI characteristics of periaqueductal lesions in multiple sclerosis. (2014) (12)
The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies (2017) (12)
Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. (2021) (12)
Gangliosides and autoimmune neuropathies: classification and clinical aspects of autoimmune neuropathies. (1994) (12)
Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. (2014) (12)
Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment (2020) (12)
Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM (2016) (12)
BG-12 Increases the Proportion of Patients Free of Clinical and Radiologic Disease Activity in Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (PD5.005) (2012) (12)
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression (2021) (12)
Magnetic resonance imaging in the evaluation of treatment in multiple sclerosis (2004) (12)
Induced changes in brain activation using a computerized attention training in patients with Multiple Sclerosis (MS) (2005) (12)
Disease control and safety in relapsing remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: a 32-week, rater- and patient-blind, randomized, parallel-group study (TOFINGO) (2013) (12)
Levels of brain‐derived neurotrophic factor in patients with multiple sclerosis (2020) (12)
Individual Assessment of Brain Tissue Changes in MS and the Effect of Focal Lesions on Short-Term Focal Atrophy Development in MS: A Voxel-Guided Morphometry Study (2016) (12)
Brain and cervical spinal cord atrophy in primary progressive multiple sclerosis: results from a placebo-controlled phase III trial (INFORMS) (2015) (12)
Measuring disability in relapsing-remitting MS (2010) (12)
Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder (2022) (12)
Cyclosporin A Treatment of Myasthenia Gravis: Initial Results of a Double‐Blind Trial of Cyclosporin A Versus Azathioprine (1987) (11)
Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. (2020) (11)
The Janus face of CNS-directed autoimmune response: a therapeutic challenge. (2002) (11)
Anti‐inflammatory disease‐modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study (2018) (11)
Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study (2014) (11)
Combinations of drugs (1996) (11)
10 years of interferon beta-1b (Betaferon®) therapy (2005) (11)
Is natalizumab overshooting its rebound? (2008) (11)
Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis. (2016) (11)
Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. (2008) (11)
Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies (2012) (11)
Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort (2020) (11)
Clinical associations of T2-weighted lesion load and lesion location in small vessel disease: Insights from a large prospective cohort study (2019) (11)
Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis (2021) (10)
Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry (2021) (10)
Fingolimod in children with Rett syndrome: the FINGORETT study (2021) (10)
Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration. (2013) (10)
Meningoradiculitis associated with giant cell arteritis (2002) (10)
Blood Neurofilament Light in Progressive Multiple Sclerosis (2022) (10)
Fingolimod-Effect on Brain Atrophy and Clinical/MRI Correlations in Three Phase 3 Studies – TRANSFORMS, FREEDOMS and FREEDOMS II (S51.006) (2013) (10)
The role of cerebellar abnormalities in neuromyelitis optica – a comparison with multiple sclerosis and healthy controls (2015) (10)
Bundle myelin fraction (BMF) mapping of different white matter connections using microstructure informed tractography (2022) (10)
Design and construction of an innovative brain phantom prototype for MRI (2018) (10)
Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★. (2019) (10)
The FSMC (Fatigue Scale for Motor and Cognitive Functions) : a new patient-reported outcome measure for cognitive and motor fatigue in multiple sclerosis (2005) (10)
Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study. (2020) (9)
Quantification of spinal cord atrophy in MS: which software, which vertebral level, spinal cord or brain MRI? A multi-centric, longitudinal comparison of three different volumetric approaches. (2018) (9)
Real-world disability improvement in patients with relapsing–remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program (2020) (9)
Oral fingolimod (FTY720) treatment reduces peripheralIL-17-producing TH17 cells in patients with multiple sclerosis (2008) (9)
["Numb chin syndrome": first presenting syndrome of multiple sclerosis?]. (2008) (9)
Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies (2018) (9)
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years (2022) (9)
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. (2015) (9)
Retinal vessels in patients with multiple sclerosis: baseline diameter and response to flicker light stimulation. (2009) (9)
MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process (vol 11, pg 471, 2015) (2015) (9)
Efficacy of Siponimod in Secondary Progressive Multiple Sclerosis: Results of the Phase 3 Study (CT.002) (2017) (9)
OPL099 Betaferon® in newly emerging multiple sclerosis for initial treatment (BENEFIT): First results (2005) (9)
Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis (2020) (9)
Oral Fingolimod (FTY720) Treatment Improves the Performance of Daily Activities Compared with Intramuscular Interferon beta-1a: Patient-Reported Indices for Multiple Sclerosis (PRIMUS)-Activities Results from a Phase III Study (TRANSFORMS) (2010) (9)
Long-term Reduction of Relapse Rate and Confirmed Disability progression after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis (2018) (9)
Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis. (2018) (9)
Study Design and Baseline Characteristics of the INFORMS Study: Fingolimod in Patients with Primary Progressive Multiple Sclerosis (P07.116) (2013) (9)
Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP) (2016) (9)
Long-Term Safety and Efficacy and Association between Baseline Treatment History and Postbaseline Relapses in Multiple Sclerosis Patients Treated with Natalizumab in the TYSABRI(R) Observational Program (TOP) (P04.134) (2012) (9)
Images in clinical medicine. Dissociation of voluntary and emotional innervation after stroke. (2010) (9)
Automatic Spinal Cord Gray Matter Quantification: A Novel Approach (2019) (9)
Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. (2022) (9)
Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials (2021) (9)
Frequency of Infections during Treatment with Teriflunomide: Pooled Data from Three Placebo-Controlled Teriflunomide Studies (P01.171) (2013) (9)
A Novel Functional Composite Endpoint to Characterize Disease Progression in Patients with Secondary Progressive Multiple Sclerosis (S12.006) (2019) (9)
Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer (2021) (9)
Clinical trials of immunosuppression and immunomodulation in multiple sclerosis (1988) (9)
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II (2022) (8)
New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis (2019) (8)
Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. (2017) (8)
Long-Term (7-Year) Data from a Phase 2 Extension Study of Fingolimod in Relapsing Multiple Sclerosis (P01.129) (2012) (8)
Ozanimod Demonstrates Efficacy and Safety in a Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase 3 Trial of Relapsing Multiple Sclerosis (SUNBEAM) (P3.396) (2018) (8)
Efficacy of Ocrelizumab in Patients with Relapsing Multiple Sclerosis: Pooled Analysis of Two Identical Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled Studies (S49.003) (2016) (8)
BG-12 (Dimethyl Fumarate) Treatment for Relapsing–Remitting Multiple Sclerosis (RRMS) Increases the Proportion of Patients Free of Measured Clinical and Neuroradiologic Disease Activity in the Phase 3 Studies (P07.106) (2013) (8)
Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging results (2007) (8)
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials (2019) (8)
T cell receptor gamma delta repertoire is skewed in cerebrospinal fluid of multiple sclerosis patients: molecular and functional analyses of antigen-reactive gamma delta clones. (1995) (8)
Quantified CSF antibody reactivity against myelin in multiple sclerosis (2015) (8)
Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis. (2006) (8)
Occurrence of MRI abnormalities in patients with isolated optic neuritis. (1990) (8)
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial (2022) (8)
A New Advanced MRI Biomarker for Remyelinated Lesions in Multiple Sclerosis (2022) (8)
Assessment of Disability in Multiple Sclerosis Using the Kinect-Camera System: A Proof-of-Concept Study (2014) (8)
Double-blind randomized multicenter dose-comparison study of interferon-β-1a (AVONEX): rationale, design and baseline data (2001) (8)
Growth differentiation factor 15 is increased in stable MS (2020) (8)
Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management (2018) (8)
Teriflunomide Slows Brain Volume Loss in Relapsing MS: A SIENA Analysis of the TEMSO MRI Dataset (P3.089) (2016) (8)
8 year follow-up of the European study of Interferon beta-1b (EUSPMS) in secondary progressive MS (2004) (7)
Teriflunomide Reduces Relapse-Related Sequelae, Hospitalizations and Corticosteroid Use: A Post-Hoc Analysis of the Phase 3 TOWER Study (P07.109) (2013) (7)
Impact of early interferon beta-1b treatment on disease evolution over five years in patients with a first event suggestive of multiple sclerosis (2008) (7)
[Multiple sclerosis: therapy with recombinant beta-1b interferon: initial results with 30 multiple sclerosis patients in northwest Switzerland]. (1996) (7)
Alemtuzumab for multiple sclerosis: who and when to treat? (2012) (7)
Efficacy and safety of interferon beta-1b sc in older RRMS patients—a posthoc analysis of the BEYOND study (2013) (7)
Clinical Efficacy of Laquinimod for the Treatment of Multiple Sclerosis; Pooled Analyses from the ALLEGRO and BRAVO Phase III Trials (S01.007) (2012) (7)
White matter lesion location correlates with disability in relapsing multiple sclerosis (2020) (7)
Lesion-to-ventricle distance and other risk factors for the persistence of newly formed black holes in relapsing–remitting multiple sclerosis (2014) (7)
Expression of the B cell-associated tyrosine kinase gene Lyn in primary neuroblastoma tumours and its modulation during the differentiation of neuroblastoma cell lines. (1992) (7)
Including Blood Neurofilament Light Chain in the NEDA Concept in Relapsing–Remitting Multiple Sclerosis Trials (S24.007) (2018) (7)
Long-term Reduction in Brain MRI Disease Activity and Atrophy after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis (2018) (7)
Immunological Predictors of Dimethyl Fumarate‐Induced Lymphopenia (2022) (7)
Impact of Ocrelizumab on Cognition in Patients at Increased Risk of Progressive Disease (P1.420) (2018) (7)
Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing–remitting multiple sclerosis (2011) (7)
Updated Incidence of Natalizumab-associated Progressive Multifocal Leukoencephalopathy (PML) and Its Relationship with Natalizumab Exposure Over Time (2815) (2020) (7)
Time to Cognitive Worsening in Patients With Relapsing Multiple Sclerosis in Ocrelizumab Phase III Trials (S44.005) (2018) (7)
Pooled Analyses from the ALLEGRO and BRAVO Trials on the Safety and Tolerability of Laquinimod as a Multiple Sclerosis Treatment (P04.132) (2012) (7)
Five-Year Follow-up of Delayed-Release Dimethyl Fumarate in RRMS: Integrated Clinical Efficacy Data from the DEFINE, CONFIRM, and ENDORSE Studies (P7.234) (2015) (7)
Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients’ assessment (2012) (7)
Comparison between balanced steady-state free precession and standard spoiled gradient echo magnetization transfer ratio imaging in multiple sclerosis: methodical and clinical considerations (2015) (7)
Impact of Siponimod on Cognition in Patients With Secondary Progressive Multiple Sclerosis: Results From Phase 3 EXPAND Study (S44.004) (2018) (7)
Erratum: The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL (Journal of Neurology (2009) 256 (405-415) DOI: 10.1007/s00415-009-0093-1) (2009) (7)
[Late manifestation of radiation injury to the plexus brachialis and plexus lumbosacralis]. (2000) (7)
Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis (2018) (7)
Natalizumab Effects during a 6-Month Dose Interruption: Relationship of Pharmacokinetic (PK), Pharmacodynamic (PD), and MRI Measurements (S41.003) (2013) (7)
Teriflunomide added to interferon-β in relapsing multiple sclerosis (2012) (6)
Detection of cerebrospinal fluid leaks by intrathecal contrast-enhanced magnetic resonance myelography. (2013) (6)
An attempt to quantify magnetic resonance imaging in multiple sclerosis — correlation with clinical parameters (2005) (6)
Long-term Safety of Fingolimod: An Interim Analysis of the LONGTERMS Cohort (S4.006) (2015) (6)
Cardiac Safety of Fingolimod 0.5 mg during the First Dose Observation in 4-Month, Open-Label, Multi-Center FIRST Study in Patients with Relapsing MS (S41.003) (2012) (6)
Central nervous system atrophy predicts future dynamics of disability progression in a real‐world multiple sclerosis cohort (2021) (6)
Long-Term Safety of Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from Phase 3 FREEDOMS II Extension Study (P01.165) (2013) (6)
A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis (2015) (6)
Hepatitis E virus infections in patients with MS on oral disease-modifying treatment (2019) (6)
Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients (2021) (6)
New aspects in the treatment of multiple sclerosis with interferon beta-1b (2004) (6)
Standardization and digitization of clinical data in multiple sclerosis (2021) (6)
Pharmacokinetics, Pharmacodynamics and Exposure-Response Analyses of Ocrelizumab in Patients With Multiple Sclerosis (N4.001) (2019) (6)
TOPIC: Efficacy and Safety of Once-Daily Oral Teriflunomide in Patients with First Clinical Episode Consistent With Multiple Sclerosis (PL2.002) (2014) (6)
Efficacy Of Fingolimod In Pre-Treated Patients With Disease Activity: Pooled Analyses Of FREEDOMS and FREEDOMS II (P3.174) (2014) (6)
Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials (2021) (6)
Ofatumumab versus teriflunomide in relapsing MS: adaptive design of two Phase 3 studies (ASCLEPIOS I and ASCLEPIOS II) (S16.005) (2017) (6)
Increased Sodium Intake Is Not Associated with MS Activity or Progression in BENEFIT (S37.002) (2016) (6)
Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive Multiple Sclerosis Treated with Ocrelizumab in the Open-label Extension Period of the Phase III ORATORIO trial (2018) (6)
BG-12 (dimethyl fumarate) and pregnancy: Preclinical studies and pregnancy outcomes reported during the clinical development program (2013) (6)
Pooled Safety Analyses from Teriflunomide Clinical Studies (P7.268) (2015) (6)
Safety and Tolerability Results From the DECIDE Study: A Phase 3 Active-Comparator Study of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis (P7.230) (2015) (6)
Daclizumab HYP Versus Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis: Primary Results of the DECIDE Study (S4.003) (2015) (6)
Classification of multiple sclerosis based on patterns of CNS regional atrophy covariance (2021) (6)
Xenogeneic Neu5Gc and self-glycan Neu5Ac epitopes are potential immune targets in MS (2020) (6)
Homing frequency of human T cells inferred from peripheral blood depletion kinetics after sphingosine-1-phosphate receptor blockade. (2013) (6)
Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP) (2020) (6)
Long-Term Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Week 96 Results of a Phase II, Randomized, Multicenter Trial (S30.006) (2012) (5)
Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities (2022) (5)
Central Slab versus Whole Brain to Measure Brain Atrophy in Multiple Sclerosis (2019) (5)
MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a. (2021) (5)
Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE (2017) (5)
Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate (2020) (5)
Efficacy of inpatient personalized multidisciplinary rehabilitation in multiple sclerosis: behavioural and functional imaging results (2020) (5)
Contributions of magnetic resonance imaging to the diagnosis of MS in isolated optic neuritis (1989) (5)
Uncoupling the Impact on Relapses and Disability Progression: Siponimod in Relapsing and Non-relapsing Patients With Secondary Progressive Multiple Sclerosis in the Phase III EXPAND Study (S8.005) (2018) (5)
Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis (2014) (5)
Short timescale modulation of cortical and cerebellar activity in the early phase of motor sequence learning: an fMRI study (2019) (5)
Changes in the Cerebrospinal Fluid and Plasma Lipidome in Patients with Rett Syndrome (2022) (5)
Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis (2021) (5)
Effect of BG-12 on Brain Atrophy and Lesions Volume: MRI Results from the DEFINE Study during First and Second Year of Treatment (IN3-2.002) (2012) (5)
ECTRIMS-EAN clinical practice guideline on pharmacological management of multiple sclerosis. (2016) (5)
Practice Effects of Mobile Tests of Cognition, Dexterity, and Mobility on Patients With Multiple Sclerosis: Data Analysis of a Smartphone-Based Observational Study (2021) (5)
Oral teriflunomide in patients with relapsing multiple sclerosis: baseline clinical features of patients in the TEMSO phase III trial (2008) (5)
Baseline Demographics and Disease Characteristics from OPERA I and II, Two Phase III Trials Evaluating Ocrelizumab in Patients with Relapsing Multiple Sclerosis (P7.201) (2015) (5)
No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP) (2021) (5)
Interferons in multiple sclerosis. (2005) (5)
Baseline Subgroup Characteristics of EXPAND: A Phase 3 Study of Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis (P3.084) (2016) (5)
Measuring treatment response to advance precision medicine for multiple sclerosis (2021) (5)
Body mass index as a predictor of MS activity and progression among participants in BENEFIT (2022) (5)
Effect of Teriflunomide on Relapses with Sequelae and Relapse Leading to Hospitalization in a Population with Relapsing Forms of Multiple Sclerosis: Results from the TEMSO Study (S30.003) (2012) (5)
Effect of teriflunomide on lymphocyte and neutrophil counts in patients with relapsing multiple sclerosis: Results from the Tower Study (2013) (5)
Can treatment effects of IFNB-1b on cognition be enhanced by additional cognitive training? (2011) (5)
The contribution of magnetic resonance imaging in the differential diagnosis of the damage of the cerebral hemispheres (2000) (5)
068 Evaluation of the long-term treatment effect of teriflunomide on cognitive outcomes and association with brain volume change: data from temso and its extension study (2018) (5)
Relapse Outcomes in Fingolimod-Treated Patients Previously Exposed to Natalizumab: Post-Hoc Analysis from the 4-Month, Open-Label FIRST Study (P07.103) (2013) (5)
Body fluid markers to monitor multiple sclerosis: the assays and the challenges (1998) (5)
The effect of BG00012 on conversion of gadolinium-enhancing lesions to T1-hypointense lesions (2008) (5)
Serum neurofilament light chain as outcome marker for intensive care unit patients (2020) (5)
Altered functional activation in MS patients with reduced attentional performance demonstrated with functional MRI (2001) (5)
Avidity of vaccine-induced influenza IgG fails to increase in fingolimod-treated patients with MS (2014) (5)
Hereditary defect of cobalamin metabolism with adolescence onset resembling multiple sclerosis: 41-year follow up in two cases (2019) (5)
Safety of Ozanimod Versus Interferon β-1a in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.006) (2018) (4)
Real-world data from over 10 years in the TYSABRI® Observational Program: Long-term safety and effectiveness of natalizumab in relapsing-remitting multiple sclerosis patients (2019) (4)
Effects of BG-12 on Magnetization Transfer Ratio in Whole Brain and Normal-Appearing Brain Tissue: Findings from the DEFINE Study (S11.004) (2012) (4)
The efficacy of natalizumab on magnetic resonance imaging (MRI) measures in patients with relapsing multiple sclerosis (MS): Results from the AFFIRM trial (2005) (4)
High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis (2022) (4)
Electronic Neurostatus-EDSS increases the quality of expanded disability status scale assessments: Experience from two phase 3 clinical trials (2020) (4)
OPL100 The effects of natalizumab on disability progression as measured by the Multiple Sclerosis Functional Composite (MSFC) and visual function in patients with relapsing MS (2005) (4)
Serum 25-hydroxyvitamin D concentrations among patients in BENEFIT predicts conversion to multiple sclerosis, MRI lesions, and brain volume loss (2012) (4)
The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis (2020) (4)
Long-Term Safety Of Fingolimod: Interim Evaluation Of Data From The LONGTERMS Trial (P2.210) (2014) (4)
Antibodies to aquaporin-4 in patients with a clinically isolated syndrome: analysis from the BENEFIT study (2008) (4)
Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS (2022) (4)
Preliminary results of the opera i and opera ii open-label extension study (2017) (4)
Predicting PML in natalizumab-treated patients: can we do better? (2013) (4)
Annualized Relapse Rate and Confirmed Disability Progression in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis (P1.366) (2018) (4)
Effect of fingolimod versus interferon-beta1a on no evidence of disease activity or worsening (NEDA-4) in the TRANSFORMS study (P4.001) (2015) (4)
Treatment of multiple sclerosis with 15 +/- deoxyspergualin. Design of a controlled study with close MRI-monitoring. (1993) (4)
Imaging multiple sclerosis pathology at 160 μm isotropic resolution by human whole-brain ex vivo magnetic resonance imaging at 3 T (2021) (4)
Safety and tolerability of fingolimod 0.5 mg during the first 4 months of administration in patients with relapsing forms of multiple sclerosis. Results from the open-label, multicentre FIRST study (2012) (4)
Microstructure-Weighted Connectomics in Multiple Sclerosis (2021) (4)
Serum and CSF Neurofilament Light Levels Predict Long-Term Outcomes in Multiple Sclerosis Patients (S50.005) (2017) (4)
Video-based pairwise comparison: enabling the development of automated rating of motor dysfunction in multiple sclerosis. (2020) (4)
MSVirtual 2020 – Late Breaking News (2020) (4)
[MRI follow-up in multiple sclerosis. A guideline for quality assurance]. (1999) (4)
Optimizing brain MRI protocols in the follow-up of patients with multiple sclerosis T2-weighted MRI of the brain after the administration of gadopentetate dimeglumine. (2005) (4)
Autoencoder as a New Method for Maintaining Data Privacy While Analyzing Videos of Patients With Motor Dysfunction: Proof-of-Concept Study (2020) (4)
The Effect of Ciclosporin versus Azathioprine on the Course of Multiple Sclerosis; Design of a Long-term Follow-up Study and Side Effects (1985) (4)
Fingolimod Reduces Annualized Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis: FREEDOMS II Study Subgroup Analysis (P07.102) (2013) (4)
A 10-year matched-pairs study comparing azathioprine and no immunosuppression in multiple sclerosis (1990) (4)
BAF312, a Selective Sphingosine 1-Phosphate Receptor Modulator, Effectively Suppresses MRI Lesion Activity in Relapsing-Remitting Multiple Sclerosis: Findings of an Adaptive Dose-Ranging Phase 2 Study (2011) (4)
Predictors of disease activity in 857 patients with MS treated with interferon beta-1b (2015) (4)
The effects of natalizumab on brain atrophy and cognitive function: results from the AFFIRM study (2006) (4)
Ocrelizumab May Reduce Tissue Damage in Chronic Active Lesions as Measured by Change in T1 Hypo-Intensity of Slowly Evolving Lesions in Patients With Primary Progressive Multiple Sclerosis (P3.376) (2018) (4)
[Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis]. (1999) (4)
Incidence of natalizumab-associated progressive multifocal leucoencephalopathy and its relationship with the pattern of natalizumab exposure over time (2019) (4)
Fingolimod reduces the number of severe relapses in patients with relapsing multiple sclerosis: Results from phase III TRANSFORMS and FREEDOMS studies (2011) (4)
Impact of informative censoring on the treatment effect estimate of disability worsening in multiple sclerosis clinical trials. (2019) (3)
Comparison of Early and Delayed Oral Laquinimod in Patients with Relapsing-Remitting Multiple Sclerosis: Effects on Disability Progression at 36 Months in the ALLEGRO Trial (S41.004) (2013) (3)
Siponimod Reduces Grey Matter Atrophy in Patients with Secondary Progressive Multiple Sclerosis: Subgroup Analyses from the EXPAND Study (1130) (2020) (3)
Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis (2021) (3)
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination (2021) (3)
MRI Analyses in RRMS Patients with Highly Active Disease: Results from FREEDOMS and TRANSFORMS Phase 3 Studies (P01.134) (2012) (3)
Phase 2 BOLD Extension Study Safety Results for Siponimod (BAF312) in Patients with Relapsing–Remitting Multiple Sclerosis (P01.176) (2013) (3)
Additive and interaction effects of working memory and motor sequence training on brain functional connectivity (2021) (3)
Accuracy of Depth-Sensing Recordings in Classifying Expanded Disability Status Scale Subscores of Motor Dysfunction in Patients with Multiple Sclerosis (I8.004) (2016) (3)
Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis (2021) (3)
BAF312, a Selective Sphingosine-1-Phosphate Receptor Modulator Improves MRI and Clinical Outcomes in Relapsing-Remitting Multiple Sclerosis (RRMS) (S30.001) (2012) (3)
Impact of fingolimod on achieving no evidence of disease activity and worsening (NEDA)-4 in previously treated patients with high disease activity (P3.246) (2015) (3)
MT-1303, a novel selective s1p1 receptor modulator in RRMS - results of a placebo controlled, double blind phase II trial (momentum) (2015) (3)
Efficacy Outcome Measures of Oral Ponesimod Compared to Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results of the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study (3972) (2020) (3)
Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials (2022) (3)
Evaluation of Teriflunomide in Children and Adolescents With Relapsing MS: TERIKIDS Phase 3 Study Design, Enrollment Update, and Baseline Data (P4.354) (2018) (3)
Clinical trials in multiple sclerosis. (2014) (3)
GNbAC1, a Humanized Monoclonal Antibody Against The Multiple Sclerosis Associated Retrovirus Envelope Protein, Is Well Tolerated In Patients With Multiple Sclerosis. (P2.217) (2014) (3)
Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis (2022) (3)
The Association Between Confirmed Disability Progression and Patient-Reported Fatigue in PPMS Patients in the ORATORIO study (S33.006) (2017) (3)
Towards a European Network for Multiple Sclerosis Trials (ENMST) (2003) (3)
Rate of Brain Volume Loss with Long-Term Delayed-Release Dimethyl Fumarate Treatment in Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Results from ENDORSE (P3.061) (2016) (3)
GAMER-MRI in Multiple Sclerosis Identifies the Diffusion-Based Microstructural Measures That Are Most Sensitive to Focal Damage: A Deep-Learning-Based Analysis and Clinico-Biological Validation (2021) (3)
The Fatigue Scale for Motor and Cognitive Functions: a recently validated instrument to assess MS-related fatigue (2007) (3)
Effect of Ocrelizumab on MRI Inflammatory and Neurodegenerative Markers of Disease in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled OPERA I and OPERA II Studies (S49.002) (2016) (3)
Safety and Efficacy of Teriflunomide for up to 9 Years in Relapsing Forms of Multiple Sclerosis: Update of the TEMSO Extension Trial (P3.150) (2014) (3)
Long-term Impact of Early MS Treatment with Interferon Beta-1b (IFNB-1b): Clinical, MRI, Employment, and Patient-Reported Outcomes (PROs) at the 11-Year Follow-up of BENEFIT (BENEFIT 11) (P7.012) (2015) (3)
Another complication of natalizumab treatment? Taking the challenge (2009) (3)
Six‐year follow‐up of a case series with non‐communicating syringomyelia in multiple sclerosis (2013) (3)
Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta‐1a (2022) (3)
Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis (2022) (3)
Vitamin D as a predictor of multiple sclerosis activity and progression. (2013) (3)
Timecourse of Treatment Effects of BG-12 (Dimethyl Fumarate) for Relapsing-Remitting Multiple Sclerosis (2013) (3)
Comparison of Patients Treated with Natalizumab and Interferon-beta/Glatiramer Using Propensity-Matched Multiple Sclerosis Registry Data (P01.211) (2013) (3)
Correlation of MRI findings and neuropsychological results in patients with multiple sclerosis (1989) (3)
Reference videos reduce variability of motor dysfunction assessments in multiple sclerosis (2018) (3)
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study (2022) (3)
Death Anxiety and Attitudes towards Death in Patients with Multiple Sclerosis: An Exploratory Study (2021) (3)
Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML (2020) (3)
EMERGING THERAPIES IN MULTIPLE SCLEROSIS (2007) (3)
061 Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE) (2018) (3)
Multiple Sclerosis Relapses Following Cessation of Fingolimod (2022) (3)
The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges (2020) (3)
GAMER MRI: Gated-attention mechanism ranking of multi-contrast MRI in brain pathology (2020) (3)
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021 (2022) (3)
Brain MRI Activity and Atrophy Measures in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis (S6.002) (2018) (3)
No influence of KIF1B on neurodegenerative markers in multiple sclerosis (2011) (3)
Proof of concept studies for tissue-protective agents in multiple sclerosis (2009) (3)
Multiple sclerosis and human T-cell lymphotropic retroviruses: negative serological results in 135 German patients (1987) (3)
Spinal cord gray matter atrophy is associated with functional decline in post‐polio syndrome (2022) (3)
Clinical and Magnetic Resonance Imaging Results From RADIANCE Part B, a Multicenter, Randomized, Double-Blind, Phase 3 Trial of Ozanimod Versus Intramuscular Interferon β-1a in Relapsing Multiple Sclerosis (RMS) (P3.410) (2018) (3)
Effect of Ocrelizumab on Disability Progression in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III, Double-Blind, Double-Dummy, Interferon Beta-1a-Controlled OPERA I and OPERA II Studies (S49.008) (2016) (3)
Predictors of Conversion to Secondary Progressive Multiple Sclerosis in Patients With Relapsing–Remitting Multiple Sclerosis (P2.393) (2018) (3)
Evolution of Cortical and White Matter Lesion Load in Early-Stage Multiple Sclerosis: Correlation With Neuroaxonal Damage and Clinical Changes (2020) (3)
clinical and MRI outcomes in multiple sclerosis (2015) (3)
Facial nerve palsy and anti-Ku autoantibodies (2012) (3)
PML risk and natalizumab: the elephant in the room (2017) (3)
Autoencoder - a new method for keeping data privacy when analyzing videos of patients with motor dysfunction (P4.001) (2018) (3)
In treatment-naive patients with relapsing-remitting multiple sclerosis (RRMS), initiating natalizumab earlier is associated with greater disability improvement than delaying treatment: real-world results from the TYSABRI® Observational Program (TOP) (P6.350) (2017) (2)
Interferon beta-16 delays progression of disability in secondary progressive multiple sclerosis — results of the european multicenter study (1998) (2)
Natalizumab increases the proportion of patients free of clinical or MRI disease activity in relapsing multiple sclerosis (2008) (2)
Impact of complement activation on clinical outcomes in multiple sclerosis (2021) (2)
[What is your diagnosis? Butterfly glioma originating from the corpus callosum]. (1992) (2)
Development and implementation of new diagnostic technologies in neurology (2022) (2)
PND63 Effects of BG-12 on Quality of Life in Relapsing–Remitting Multiple Sclerosis: Findings From the Phase 3 Define Study (2012) (2)
Interferon-beta-1b reduces development of T1 black holes on MRI in secondary progressive multiple sclerosis (2000) (2)
The FSMC (Fatigue Scale for Motor and Cognitive functions) : first results from a multicentre validation study on a new patient reported outcome measure for cognitive and motor fatigue in multiple sclerosis (2006) (2)
Fingolimod Effects on PASAT Score and Baseline Determinants of PASAT in a Large Cohort of RRMS Patients (P2.150) (2016) (2)
Antibodies to aquaporin-4 in patients with a clinically isolated syndrome: analyses from the BENEFIT study (BEtaferon (R) in Newly Emerging multiple sclerosis For Initial Treatment) (2008) (2)
Application of the revised version of the 2010 McDonald diagnostic criteria: retrospective comparison using the BEN-EFIT clinical study dataset (2012) (2)
PO129 Neda analysis by epoch in the opera studies of ocrelizumab (2017) (2)
PND3 Relapses Requiring Intravenous Steroids and Multiple Sclerosis-Related Hospitalizations: Findings From the Phase 3 Define and Confirm Studies (2012) (2)
Progress in understanding inflammatory and autoimmune diseases of the central nervous system (2009) (2)
Indirect Comparisons of Oral Fingolimod Versus Natalizumab on Measures of Disease Freedom Based on Results from FREEDOMS and AFFIRM (P01.209) (2013) (2)
4-Year Follow-up of Delayed-Release Dimethyl Fumarate Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS): Integrated Clinical Efficacy Data From DEFINE, CONFIRM, and the ENDORSE Extension Study (P3.173) (2014) (2)
Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies (2022) (2)
Neurofilament Light Chains as a Marker of Concurrent and Future Active Disease in Relapsing Multiple Sclerosis: An Analysis of Baseline Data From the Phase 3 Ozanimod Clinical Trials (S56.006) (2019) (2)
Benefits of cognitive training in MS patients treated with INFB-1b (2011) (2)
Long-term Efficacy and Safety of Siponimod in Patients with SPMS: EXPAND Extension Analysis Up to 5 Years (4128) (2020) (2)
Effect of Delayed-Release Dimethyl Fumarate on No Evident Disease Activity in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis Patients: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P7.247) (2015) (2)
The efficacy of BG00012 in patients with relapsing-remitting multiple sclerosis: Subgroup analyses from the phase 2B study (2008) (2)
Letter Re: Retraction: Risedronate Therapy For Prevention Of Hip Fracture After Stroke In Elderly Women; Risedronate Therapy For Prevention Of Hip Fracture After Stroke In Elderly Women: Reply From The Authors (2017) (2)
Database for serial magnetic resonance imaging in multiple sclerosis (2004) (2)
Long-term safety and efficacy of natalizumab and assessment of 2-year freedom from clinical disease activity in patients with multiple sclerosis in the TYSABRI(R) observational programme (2012) (2)
New criteria for the diagnosis of multiple sclerosis (2005) (2)
MRI and assessment of treatment in multiple sclerosis. (2001) (2)
Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS (2022) (2)
Daclizumab HYP Reduced Brain MRI Lesion Activity Compared With Interferon Beta-1a: Results from the DECIDE Study (P7.252) (2015) (2)
Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis (2019) (2)
Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multicentre FIRST study in relapsing multiple sclerosis patients (2012) (2)
Five-Year Follow-up of Delayed-Release Dimethyl Fumarate in Relapsing-Remitting Multiple Sclerosis: MRI Outcomes from DEFINE, CONFIRM, and ENDORSE (P7.262) (2015) (2)
Individual assessment of chronic brain tissue changes in MRI – the role of focal lesions for brain atrophy development. A Voxel-Guided Morphometry study (2008) (2)
MRI monitoring of cerebral atrophy during a placebo-controlled trial of interferon-beta-1b in secondary progressive multiple sclerosis (2000) (2)
Teriflunomide Slows Brain Volume Loss: Subgroup Analysis of the SIENA TEMSO MRI Dataset (P3.052) (2016) (2)
Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Relapsing Multiple Sclerosis in the OPERA I and OPERA II Trials (2018) (2)
Search for retroviral sequences in peripheral blood mononuclear cells and brain tissue of multiple sclerosis patients (1990) (2)
Prognostic relevance of antimyelin antibodies for progression to multiple sclerosis after a first demyelinating event: results from the BENEFIT study (2006) (2)
Usability and acceptability of ASSESS MS: a system to support the assessment of motor dysfunction in Multiple Sclerosis using depth-sensing computer vision (2015) (2)
Ocrelizumab in multiple sclerosis: risks and benefits – Author's reply (2012) (2)
Normalized brain volume predicts cognitive performance in MS: an analysis of a large cohort from fingolimod phase III studies (P7.284) (2015) (2)
4-31-17 MRI protocol for the European trial of beta interferon-1b in secondary progressive multiple sclerosis (1997) (2)
Safety and tolerability results of a phase 2b extension study of the novel oral fumarate BG00012 for the treatment of relapsing-remitting multiple sclerosis (2007) (2)
Natalizumab-Treated Patients with Multiple Sclerosis Have Low Rates of Brain Volume Decrease and Low MRI Disease Activity in the Long-term STRATA Study (P7.260) (2015) (2)
Automated quantification of motor dysfunction in multiple sclerosis using depth-sensing computer vision (P3.213) (2015) (2)
Real-World Safety and Efficacy of Natalizumab after Switching from Other Disease-Modifying Therapies (DMTs): Data from the Tysabri® Observational Program (TOP) (P2.069) (2016) (2)
Use of composite scores in the quantification of deterioration in multiple sclerosis (1999) (2)
SclerosisMyelin Surface Antigen in Pediatric Multiple Age-Dependent B Cell Autoimmunity to a (2009) (2)
Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis (2022) (2)
Long-term effect of early treatment with interferon-beta-1b after a first clinical event suggestive of multiple sclerosis: 8-year observational extension of the phase 3 BENEFIT trial (2011) (2)
Early Initiation of Interferon Beta-1b after a First Clinical Event Suggestive of Multiple Sclerosis: Clinical Outcomes and Use of Disease-Modifying Therapy from the BENEFIT Extension Study (PD5.002) (2012) (2)
Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS (2022) (2)
Re: Short-term brain atrophy changes in relapsing-remitting multiple sclerosis. (2005) (2)
The FSMC (Fatigue scale for motor and cognitive functions) : a new instrument to assess MS-related fatigue (2007) (2)
Neuroprotection in multiple sclerosis report from the MS Forum 16th Modern Management Workshop, March 2004, Cernobbio, Italy. (2004) (2)
Longitudinal Spatiotemporal Distribution of Gray and White Matter Pathology in Multiple Sclerosis (2010) (2)
145 Long-term safety of ofatumumab in patients with relapsing multiple sclerosis (2022) (2)
Brain atrophy measurement over a MRI scanner change in multiple sclerosis (2022) (2)
Comparison of Switching to Natalizumab Versus Remaining on Interferon-Beta or Glatiramer Acetate after On-Treatment MS Relapse Using Propensity-Matched Registry Data (P7.208) (2014) (2)
Effect of BG-12 in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (P01.130) (2012) (2)
Safety and Pharmacokinetics of GNbAC1, a Humanised Monoclonal Antibody Against the Multiple Sclerosis Retrovirus Envelope Protein in Patients with Multiple Sclerosis (S31.003) (2013) (2)
Prediction of expanded disability status scale subscores of motor dysfunction in multiple sclerosis using depth-sensing computer vision (2015) (1)
[Multiple sclerosis: diagnostic procedures and current therapeutic developments]. (1995) (1)
Ongoing Safety and Effectiveness: An Interim Analysis of Long-Term Fingolimod Treatment (P3.057) (2016) (1)
Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies (2012) (1)
Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis (2019) (1)
The spatio-temporal relationship between white matter lesion volume changes and brain atrophy in clinically isolated syndrome and early multiple sclerosis (2022) (1)
Relapses Requiring Intravenous Steroid Use and Multiple Sclerosis (MS)-Related Hospitalizations: An Integrated Analysis of the BG-12 (Dimethyl Fumarate) Phase 3 Studies (P07.121) (2013) (1)
[Neurological complications of HIV infection. Review: new diagnostic, therapeutic and prognostic aspects]. (2000) (1)
Longer-term Safety with Siponimod Treatment in Multiple Sclerosis: Pooled Analysis of Data from the Bold and Expand Trials and their Extensions (2018) (1)
Interferon beta-1a and beta-1b for treatment of multiple sclerosis (2002) (1)
Rapid Onset of Ocrelizumab Suppression of Brain MRI Activity in Relapsing-Remitting Multiple Sclerosis (S12.008) (2017) (1)
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis (2023) (1)
Genetic modification of 25(OH)D levels in MS (2014) (1)
Interferons in relapsing remitting multiple sclerosis (2003) (1)
Four-year Expanded Disability Status Scale (EDSS) Outcomes in Patients Treated with Fingolimod in the Phase 3 and Extension Trial Program (P3.185) (2014) (1)
OP24 – 2321: FINGORETT – An ongoing phase I clinical study to assess safety and efficacy of oral fingolimod (FTY720) in children with Rett syndrome (2015) (1)
Impact of cumulative dose and time on magnetic resonance imaging and clinical outcomes during long-term treatment with subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: exploratory analyses (2009) (1)
Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS (2022) (1)
Effects of BG-12 on Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (P07.102) (2012) (1)
No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon β-1a. (2019) (1)
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (2022) (1)
Effect of Delayed-Release Dimethyl Fumarate on Freedom from Measured Clinical and Neuroradiological Disease Activity in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: An Integrated Analysis of DEFINE and CONFIRM (P3.159) (2014) (1)
Pain in patients with multiple sclerosis: Effects of natalizumab (2008) (1)
Laminar analysis of the cerebellar cortex shows widespread damage in early MS patients: A pilot study at 7T MRI (2020) (1)
Infrared depth sensor based automated classification of motor dysfunction in multiple sclerosis - a proof-of-concept study (2014) (1)
[Multiple sclerosis and its delimitation from other diseases. Case report examples with differential diagnostic considerations]. (1990) (1)
Contribution of CSF to the Diagnosis of McDonald MS: Retrospective Analysis in the BENEFIT Study (P03.235) (2013) (1)
Combined visual, motor and somatosensory evoked potentials as markers of clinical disability in early multiple sclerosis (2007) (1)
Real-world improvement across functional systems (FS) in relapsing-remitting multiple sclerosis (RRMS) patients treated with natalizumab in the TYSABRI® Observational Program (TOP) (P6.383) (2018) (1)
Six-year follow-up of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: MRI outcomes from DEFINE, CONFIRM and ENDORSE (2015) (1)
Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high‐dose pharmaceutical‐grade biotin (MD1003) (2020) (1)
Efficacy Benefits Of Fingolimod 0.5 mg Once Daily In Patients Previously Treated With Glatiramer Acetate: Pooled Analysis Of The Phase 3, Placebo-Controlled FREEDOMS and FREEDOMS II Studies In Relapsing Multiple Sclerosis (P3.193) (2014) (1)
Effect of Fingolimod in Patients with No Disability as Measured by EDSS at Baseline: Post-Hoc Analyses of FREEDOMS I and II (P07.124) (2013) (1)
Baseline Predictors of Disease Activity in Patients with CIS Treated with Interferon beta-1b in the BENEFIT 11 Trial (P2.121) (2016) (1)
Betaferon(R) in newly emerging multiple sclerosis for initial treatment (BENEFIT): Clinical outcomes (2006) (1)
Mitochondrial cytopathy with common MELAS mutation presenting as multiple system atrophy mimic (2016) (1)
Case-based approach to evaluate the efficacy of working memory training in juvenile Multiple Sclerosis (2013) (1)
Effect of Fingolimod on Confirmed Improvement in Physical Disability: Post-Hoc Analyses of FREEDOMS I and TRANSFORMS (P07.108) (2013) (1)
B-cell Depletion and Efficacy Outcomes with Ofatumumab: Subgroup Analysis From the Pooled Phase 3 ASCLEPIOS I and II Trials (2356) (2020) (1)
Sustained low rate of brain volume loss with long-term delayed-release dimethyl fumarate treatment in relapsing-remitting multiple sclerosis patients: results from the ENDORSE study (2015) (1)
The incidence and clinical significance of antibodies to natalizumab over 2 years of treatment in patients with multiple sclerosis (2006) (1)
Vitamin D and the development and evolution of permanent black holes among patients with clinically isolated syndrome (2015) (1)
Vancouver Consortium of MS Centers' Magnetic Resonance Imaging Guidelines. (2003) (1)
Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis. (2017) (1)
Intracranial aneurysms. (1997) (1)
A confusing patient’s history: small or large vessel vasculitis? (2010) (1)
The central vein sign on cerebral 3T MRI in multiple sclerosis - a multi-center investigation under the auspices of the MAGNIMS study group. (2018) (1)
Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study (2022) (1)
BG-12 effects on quality of life in relapsing–/INS;remitting ms patients: Integrated analysis of the Phase 3 DEFINE and CONFIRM studies (2013) (1)
No consensus about consensus? (2021) (1)
Monitoring of Subclinical Disease Activity by Serum Neurofilament Light Chain Levels in Multiple Sclerosis (S37.005) (2019) (1)
Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis. (2022) (1)
ACTRIMS-ECTRIMS MSBoston 2014: Late Breaking News Poster Session (2014) (1)
Betaferon (R)/betaseron (R) in newly emerging multiple sclerosis for initial treatment (benefit): Effects of early vs. delayed treatment with interferon beta-1B (2007) (1)
correlations of balance instability with disability in multiple sclerosis patients : p411 (2011) (1)
Predicting multiple sclerosis: a large international multicentre study (2015) (1)
Longitudinal modeling of MS patient trajectories improves predictions of disability progression (2020) (1)
Effect of Ocrelizumab on Visual Outcomes in Patients with Baseline Visual Impairment in the OPERA Studies in Relapsing Multiple Sclerosis (2018) (1)
Baseline characteristics and patient adherence in the BENEFIT study (2005) (1)
Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial (2023) (1)
A comparative assessment of myelin-sensitive measures in multiple sclerosis patients and healthy subjects (2022) (1)
Disease Course in Multiple Sclerosis (MS) Patients Switching from Fingolimod to Natalizumab (P3.284) (2015) (1)
Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, Decreases Neurofilament Light Chain Levels Over 2.5 Years of Treatment in Patients with Relapsing Multiple Sclerosis (2023) (1)
FV 47 Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis (2019) (1)
The effects of natalizumab on disability progression in the AFFIRM study: correlation between changes in Multiple Sclerosis Functional Composite and Expanded Disability Status Scale scores (2005) (1)
Erratum: Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: A phase 3b, open-label study (Journal of Neurology (2014) 261 (267-276) DOI: 10.1007/s00415-013-7115-8) (2014) (1)
[Oral disease modifying therapy of multiple sclerosis: the current view]. (2014) (1)
Setwise comparison: efficient fine-grained rating of movement videos using algorithmic support – a proof of concept study (2020) (1)
The effect of fingolimod on T1-hypointense lesions developed on-study and evolution of pre-existing Gd+ lesions, stratified by lesion size: A posthoc analysis of FREEDOMS study (P7.245) (2015) (1)
Predicting the On-Study Relapse Rate for Multiple Sclerosis Patients in Clinical Trials (2005) (1)
Ocrelizumab Safety in Patients with Multiple Sclerosis: Updated Analyses with a Focus on Infusion-Related Reactions (2018) (1)
Clinically Meaningful Decline on SDMT Primarily Occurs Independently of Relapses and Is Slowed by Ocrelizumab in Patients with Multiple Sclerosis: Results from the Pooled OPERA Studies (1290) (2020) (1)
Estimating the Onset of Efficacy With Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis (P7.214) (2014) (1)
Quantification of MS lesion evolution in a serial MRI study (2001) (1)
EFFECT OF TERIFLUNOMIDE ON LYMPHOCYTE AND NEUTROPHIL COUNTS (2015) (1)
Recurrent disability progression endpoints in multiple sclerosis clinical trials (2022) (1)
Baseline magnetic resonance imaging predictors for conversion to clinically definite multiple sclerosis and McDonald multiple sclerosis, based on integrated 3-year data from the BENEFIT study (2008) (1)
SWITCHING THERAPY TO FINGOLIMOD IMPROVES CLINICAL AND MRI OUTCOMES (2014) (1)
Investigating the Effect of Teriflunomide on Diffuse Brain Tissue Damage in the Phase 3 TEMSO Study (2018) (1)
Safety and Efficacy of Siponimod (BAF312) in Patients with Relapsing-remitting Multiple Sclerosis: Results from Dose-blinded Extension Phase of BOLD Study (P3.151) (2014) (1)
HEREDITARE MOTORISCH-SENSIBLE NEUROPATHIEN (1995) (1)
Time to Change the Current Clinical Classification of Multiple Sclerosis? (2022) (1)
Dose Titration Regimen Attenuates Bradyarrhythymic Events with BAF312 during Treatment Initiation (P01.131) (2012) (1)
Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references (2021) (1)
Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials (2022) (1)
No Evidence of Disease Activity on Ocrelizumab Treatment in Patients With Early Relapsing Multiple Sclerosis: Pooled Analysis of the Phase III OPERA Studies (P4.391) (2017) (1)
[Reversible dementia]. (1998) (1)
Three-year follow-up of oral BG-12 (dimethyl fumarate) treatment in relapsing remitting multiple sclerosis (RRMS): integrated magnetic resonance imaging (MRI) outcomes from DEFINE, CONFIRM, and ENDORSE (2013) (1)
Autoencoder as a New Method for Maintaining Data Privacy While Analyzing Videos of Patients With Motor Dysfunction: Proof-of-Concept Study (Preprint) (2019) (1)
Proportion Of Patients With Brain Volume Loss Comparable To Healthy Adults In Fingolimod Phase 3 Multiple Sclerosis Studies (S13.006) (2014) (1)
PML with dimethyl fumarate—No convincing case against natalizumab (2019) (1)
Comparative Efficacy of Switching to Natalizumab Versus Switching to Interferon-Beta or Glatiramer Acetate after On-Treatment MS Relapse Using Propensity-Matched Registry Data (P3.175) (2014) (1)
Both spinal cord volume and spinal cord lesions impact physical disability in multiple sclerosis (2013) (1)
Multiple Sclerosis Patients with No Evidence of Disease Activity in the 2-Year AFFIRM Study Have Better Outcomes with Long-term Natalizumab Treatment than Patients Who Had Evidence of Disease Activity in AFFIRM (P7.221) (2015) (1)
Patients Free of Clinical MS Activity in TEMSO and TOWER: Pooled Analyses of Two Phase 3 Placebo-Controlled Trials (P3.164) (2014) (1)
Effect of Delayed-Release Dimethyl Fumarate on Health-Related Quality of Life in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients According to Prior Therapy: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P3.162) (2014) (1)
Efficacy of Ozanimod Versus Interferon β-1a by Prior Treatment and Baseline Disability in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B) (S36.005) (2018) (1)
Long-term Follow-up of the Effect of Delayed-Release Dimethyl Fumarate on No Evidence of Disease Activity in Patients with Multiple Sclerosis (P7.280) (2015) (1)
[Diagnosis and differential diagnosis in multiple sclerosis]. (1997) (1)
Video-based paired-comparison ranking: A validation tool for fine grained measures of motor dysfunction in multiple sclerosis (2014) (1)
Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180] (2021) (1)
Safety profile of BG00012, all oral formulation of dimethyl fumarate for patients with relapsing MS (2008) (1)
Five-year follow-up of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: MRI outcomes from DEFINE, CONFIRM, and ENDORSE (2014) (1)
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. (2023) (1)
Subcutaneous interferon β-1a three times weekly and the natural evolution of gadolinium-enhancing lesions into chronic black holes in relapsing and progressive multiple sclerosis: Analysis of PRISMS and SPECTRIMS trials (2017) (1)
A Long-term Experience with Fingolimod: Evaluation of Safety, Disability, and Treatment Satisfaction in Patients with Relapsing–Remitting Multiple Sclerosis (P6.377) (2018) (1)
Brain Volume as a Predictor of Disability in Primary Progressive Multiple Sclerosis: Evidence from the INFORMS Trial (S51.007) (2016) (1)
Effects of interferon beta-1 b on cognitive performance in patients with a first event suggestive of multiple (2012) (1)
Neutralising antibodies do not affect efficacy of interferon beta-1b: further analysis of the BEtaferon (R) in Newly Emerging multiple sclerosis For Initial Treatment study (BENEFIT) (2008) (1)
Natalizumab improves health-related quality of life in patients with relapsing multiple sclerosis (2006) (1)
Sustained Low Rate of Brain Volume Loss under Long-term Delayed-Release Dimethyl Fumarate Treatment in Relapsing-Remitting Multiple Sclerosis Patients: Results from the ENDORSE Study (P7.243) (2015) (1)
The BENEFIT studies: adherence, tolerability and quality of life with Betaferon((R)) treatment after a first event suggestive of multiple sclerosis (2008) (1)
Predicting conversion to clinically definite multiple sclerosis using machine learning on the basis of cerebral grey matter segmentations (2015) (1)
PO114 Neda achievement by time interval with daclizumab (2017) (0)
Long Term Treatments II 5 November 1997, Tuesday (1997) (0)
Betaferon(R) in newly emerging multiple sclerosis for initial treatment (BENEFIT): Subgroup analysis (2006) (0)
Interdisziplinäres Risikomanagement in der Therapie der multiplen Sklerose (2016) (0)
Abstract withdrawn (2010) (0)
Evaluation of a computerized cognitive training program in patients with impaired working memory functions (2008) (0)
Interferon-&bgr;1b in the treatment of secondary progressive MS: Impact on quality of life (2001) (0)
T-cell autoreactivity against self glycosphingolipids in multiple sclerosis (2001) (0)
Neutralising Antibodies to Interferon Β Authors' Reply (0)
Relating functional reorganisation in multiple sclerosis to clinical measures in a multi-centre study (2006) (0)
Grey and white matter atrophy in a large cohort of multiple sclerosis patients : Relation to MRI parameters and impact on clinical disability (2011) (0)
Sample sizes for brain atrophy outcome measures in clinical trials for secondary progressive multiple sclerosis (2008) (0)
Autologous stem cell transplantation in multiple sclerosis: preliminary clinical results and future activities (2001) (0)
Reader Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis (2022) (0)
[Diagnosis and therapy of polyneuropathy in old age]. (1991) (0)
Predicting Response To Interferon beta-1b Therapy In Patients With Clinically Isolated Syndrome (P1.228) (2014) (0)
What is new in MS spasticity research? Poster session highlights. (2015) (0)
034 Updated safety analysis of ocrelizumab in multiple sclerosis (2022) (0)
Utility of tract based spatial statistics ( TBSS ) to discriminate subgroups of Multiple Sclerosis patients (2008) (0)
FP33-WE-01 TYSABRI® observational program: a long-term evaluation of safety and impact on disease activity and progression of natalizumab in relapsing-remitting MS (2009) (0)
Reversibility of Natalizumab Effects on Peripheral Immune Cell Dynamics in Patients with Multiple Sclerosis (2017) (0)
Title : Sodium intake and multiple sclerosis activity and progression in BENEFIT Running Head : No link between sodium and MS outcomes (2017) (0)
Investigating the effect of teriflunomide on diffuse cortical grey matter volume loss in the phase 3 TOPIC study (2019) (0)
021 Determinants of natalizumab-associated PML outcomes (2022) (0)
[Comments on outpatient psychiatric-psychotherapeutic treatment by practising neurologist (author's transl)]. (1981) (0)
2015 Multiple Sclerosis Experts Summit. (2015) (0)
Improving Detection of Change in Motor Functioning in Multiple Sclerosis Using Video-Assisted Composite Measures. (2022) (0)
Multimodal evoked potentials in primary progressive MS: A potential biomarker for prognosis and course (P2.350) (2017) (0)
Prognostic relevance of antimyelin antibodies for the progression to multiple sclerosis after a first demyelinating event: Results of the BENEFIT trial (2006) (0)
Clinicopathological correlations for black holes: an MRI marker for axonal loss? (2001) (0)
018 Disease control beyond NEDA: the value of non-clinical measures to determine treatment response to natalizumab (2022) (0)
Assessment of Multiple Aspects of Upper Extremity Function Independent From Ambulation in Patients with Multiple Sclerosis (2023) (0)
[Immunosuppressive therapy of multiple sclerosis using cyclosporin A and azathioprine. Long-term effects, risks, proton spin tomography and immunological findings]. (1990) (0)
Predictors of disease activity in patients with clinically isolated syndrome (CIS) treated with interferon beta 1b in the BENEFIT trial (2013) (0)
Impact of sustained disability progression and relapses on visual outcomes in the AFFIRM trial (2007) (0)
Heterologous gene expression of a novel brain-specific protein tyrosine kinase. (1994) (0)
Focal Cortical and Periventricular Damage Alters Global Brain Networks in Multiple Sclerosis Patients Hereby Affecting Information Processing Speed (2022) (0)
Serial 1H MRS of Gd-enhancing MS plaques: Observations during 24 Months (1995) (0)
Safety and Immunogenicity of Two Dosing Frequencies of Subcutaneous Interferon (scIFN) β-1a in Patients with a First Clinical Demyelinating Event (FCDE): 5-year Results of Phase III, Double-blind, Multicenter Trials (REFLEX/REFLEXION) (P7.211) (2015) (0)
Relationship between baseline treatment history and post baseline relapses and serious adverse events in natalizumab-treated patients with multiple sclerosis (2011) (0)
[What is your diagnosis? Chloroquine-induced neuromyopathy]. (1991) (0)
Impact of early treatment of MS with interferon beta-1b: cognitive outcomes at the 11-year follow-up of BENEFIT (BENEFIT 11) (2015) (0)
Daclizumab HYP reduces total disability burden of patients with multiple sclerosis: results from an exploratory area under the curve analysis (2015) (0)
023 Relapse outcomes with natalizumab Q4W vs switch to Q6W (2022) (0)
The relationship between disease severity and health-related quality of life in patients with relapsing multiple sclerosis (2006) (0)
Real-World Relapsing-Remitting Multiple Sclerosis (RRMS) Patients in the Tysabri® Observational Program (TOP) Who Discontinued Natalizumab: Why They Stopped, Which Therapies They Switched To, and How Their Disease Activity Changed (P2.399) (2017) (0)
Vitamin D as a Predictor of Functional Deficits in Multiple Sclerosis (P4.014) (2015) (0)
[Results of the third survey of the structure of neurological inpatient services in former West German districts including West-Berlin]. (1992) (0)
[Stress-related vertical double vision and ptosis]. (2009) (0)
Measures of Early Clinical Activity as Prognostic Factors for Long-Term Clinical Outcomes in Relapsing-Remitting Multiple Sclerosis (2010) (0)
Effect of early initiation or switch to fingolimod on relapse outcomes in patients with relapsing-remitting multiple sclerosis: Pooled analysis from Phase 3 and Real-World studies (2017) (0)
Evolution of Multiple Sclerosis Lesions : Preliminary Results from Quantitative Magnetization Transfer Imaging (2012) (0)
Axonal and myelin injury in white matter and cortex of relapsing-remitting and progressive multiple sclerosis patients: a combined myelin water and multi-shell diffusion MRI study (2019) (0)
Electrophysiological surrogate markers for primary progressive multiple sclerosis (PPMS) – cross-sectional analysis of 23 patients (2008) (0)
Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Delayed-Release Dimethyl Fumarate: A Three-Year Interim Analysis of ENDORSE (P7.236) (2015) (0)
[Data on the structure of neurologic inpatient care centers in West Germany]. (1982) (0)
Optical coherence tomography and ophthalmological findings in patients with CIS treated with interferon beta-1b: 11-year follow-up in BENEFIT (BENEFIT 11) (2015) (0)
Interferon beta in the treatment of multiple sclerosis--closing remarks. (1995) (0)
Predicting long-term sustained disability progression in multiple sclerosis (2019) (0)
Effects of medication and cognitive training on alertness function in patients with multiple sclerosis (2008) (0)
P2.57: Modelling Time to Progression in Multiple Sclerosis (2004) (0)
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci | NOVA. The University of Newcastle's Digital Repository (2011) (0)
Adding brain volume loss to the modified Rio scoring system improves prediction of future disability progression: Analyses from fingolimod Phase III trials (P5.202) (2015) (0)
R2*based iron mapping in multiple sclerosis: a multicentre study (2012) (0)
A randomised, placebo-controlled phase II trial of a novel oral single-agent fumarate therapy, BG00012, in patients with relapsing-remitting multiple sclerosis (2005) (0)
Neurostatus e-Scoring Increases Quality of the Expanded Disability Status Scale (EDSS) Assessments: First Experience in a Phase 3 Clinical Trial with Siponimod in Secondary Progressive Multiple Sclerosis (P2.112) (2016) (0)
Progression Independent of Relapse Activity (PIRA) in Patients with Relapsing Multiple Sclerosis (2019) (0)
[Hereditary motor and sensory neuropathies. Clinical and molecular genetic aspects]. (1995) (0)
Rethinking MS in Europe: Prioritising Timely, Integrated Care for People with Multiple Sclerosis (2020) (0)
Monthly screening for neuropsychological impairment in multiple sclerosis (2007) (0)
Clinical Efficacy of Laquinimod 0.6 mg Once Daily in the Treatment of Worsening Relapsing-Remitting Multiple Sclerosis (Baseline EDSS >3) (P3.051) (2016) (0)
Patient-Reported Quality of Life in the BENEFIT Trial (P4.180) (2014) (0)
Betaferon(R) in newly emerging multiple sclerosis for initial treatment (BENEFIT): Safety, tolerability, and adherence (2006) (0)
Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies (2022) (0)
Detection of subtle white matter abnormalities in relapsing-remitting MS - Q-space analysis of the slow diffusion component (2005) (0)
F.14. Autoantibodies to Myelin Oligodendrocyte Glycoprotein in Pediatric MS (2008) (0)
NfL as a Predictor of GdE Lesions in Patients With Relapsing Multiple Sclerosis Treated With Ozanimod in the Phase 2 RADIANCE Trial (P1-3.012) (2023) (0)
Magnetic resonance imaging results from AFFIRM: a randomised controlled trial of natalizumab in patients with relapsing multiple sclerosis (2005) (0)
Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study. (2023) (0)
The MSBase global registry: a web platform for collaborative multiple sclerosis outcomes research (2005) (0)
3-Year Follow-up of Oral BG-12 (Dimethyl Fumarate) for Relapsing-Remitting Multiple Sclerosis (RRMS): Integrated MRI Outcomes from the DEFINE, CONFIRM, and ENDORSE studies (2014) (0)
An investigation of the association between focal damage and global network properties in cognitively impaired and cognitively preserved patients with multiple sclerosis (2023) (0)
MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry (2018) (0)
Alertness dysfunction in MS: structural lesions and functional consequences (2007) (0)
Personalized maps of T1 relaxometry abnormalities provide correlates of disability in multiple sclerosis patients (2023) (0)
178 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis (2019) (0)
Mental toughness , sleep disturbances , and physical activity in patients with multiple sclerosis ( MS ) compared to healthy adolescents and young adults-a pilot study (2016) (0)
Baseline characteristics, treatment efficacy, and serious adverse events in natalizumab-treated MS patients without prior treatment (2012) (0)
Whole spinal cord MRI as a routine screening examination in multiple sclerosis – use of parallel imaging (2006) (0)
Mechanisms of disability in relapse onset multiple sclerosis of long disease duration (2012) (0)
The effects of natalizumab on disability and health-related quality of life in patients with relapsing MS (2006) (0)
The BENEFIT study: characteristics of patients with potentially benign multiple sclerosis (2007) (0)
International magnims-CMSC-NAIMS consensus recommendations on the use of standardized MRI in MS (2021) (0)
147 Siponimod preserves retinal thickness: findings from the EXPAND OCT substudy (2022) (0)
Usability and acceptability of the ASSESS MS movement recording tool in Multiple Sclerosis using depth-sensing computer vision (P3.220) (2015) (0)
Otto van Eikema Hommes – 7 February 1932 – 16 August 2022 (2022) (0)
Long-term Disease Control with Fingolimod in RRMS Patients with Active Disease (2018) (0)
Design of the RECORD MS study and pregnancy registry in patients with multiple sclerosis receiving cladribine tablets therapy in normal medical care (2011) (0)
LONGITUDINAL-STUDY ON CORRELATIONS BETWEEN DISABILITIES AND CEREBRAL MR CHANGES IN MULTIPLE-SCLEROSIS (1994) (0)
Neurologist-in-training : Multiple sclerosis (0)
Laquinimod Disability Progression Effects Are Maintained with Increasingly Rigorous Confirmation Time Intervals (P3.069) (2016) (0)
Erratum to: Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study (2014) (0)
Natalizumab treatment interruption: RESTORE study baseline data (2011) (0)
Practice Effects in Mobile Tests of Cognition, Dexterity & Mobility in Multiple Sclerosis Patients: Data Analysis of a Smartphone–Based Observational Study (Preprint) (2021) (0)
Cerebellar cortical laminar analysis of T1 relaxation times at 7T MRI shows widespread cerebellar cortex damage in early relapsing-remitting MS patients but no correlation with clinical deficits (2019) (0)
Delayed−Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes Reported During the Clinical Development Program (S24.006) (2014) (0)
[Cell depletion and myoablation for neuroimmunological diseases]. (2016) (0)
The RADIANCE and SUNBEAM phase 3 studies of ozanimod in relapsing multiple sclerosis: study design and baseline characteristics (P6.344) (2017) (0)
Onset of clinical andMRI e ffi cacy of ocrelizumab in relapsing multiple sclerosis (0)
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial (2022) (0)
Predictors of Disease Activity in 857 MS Patients Treated with IFNB-1b (PD5.009) (2012) (0)
Treating Systematic Errors in Multiple Sclerosis Data (2005) (0)
Longitudinal Clinical and MRI Outcomes in Relapsing Multiple Sclerosis (RMS) Patients After Short-term Ponesimod Treatment Interruption and Re-initiation (P6-3.007) (2023) (0)
Automation of clinical assessments via machine learning and paired comparisons (P4.205) (2015) (0)
Lymphocyte Dynamics During and After Fingolimod Therapy: Long-Term Data from the INFORMS Trial (P5.294) (2016) (0)
The incidence and clinical significance of antibodies to natalizumab: 2-year results from the AFFIRM study (2005) (0)
Sa.32. The Immunogenicity of Natalizumab in Patients with Multiple Sclerosis (2006) (0)
The effect of natalizumab on brain atrophy and its relationship with cognitive function in multiple sclerosis (2006) (0)
Efficacy and Safety of Continuous Fingolimod Treatment for At Least 5 Years in Patients with Relapsing-remitting Multiple Sclerosis: Analysis of Long-term Data (2018) (0)
Natalizumab in relapsing multiple sclerosis: appropriate patient selection, management guidelines, and a diagnostic algorithm for the differential diagnosis of new neurologic signs or symptoms (2006) (0)
020 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years (2022) (0)
Computer-based working memory training in patients with multiple sclerosis : design of a randomised study (2006) (0)
multiple sclerosis-related fatigue The Fatigue Scale for Motor and Cognitive Functions ( FSMC ) : validation of a new instrument to assess (2009) (0)
[Facial myokymia caused by pontine lesions and central fever in multiple sclerosis--case report]. (1991) (0)
Molecular dissection of the role of vitamin D in determining multiple sclerosis activity (2013) (0)
MRI results in patients with CIS treated with interferon beta-1b: 11-year follow up in BENEFIT (BENEFIT 11) (2015) (0)
Protein kinases expressed in aggregating brain cell cultures during myelination. (1993) (0)
4-year follow-up of delayed-release dimethyl fumarate treatment in relapsing-remitting multiple sclerosis (RRMS): integrated MRI outcomes from DEFINE, CONFIRM, and the ENDORSE extension study (2014) (0)
144 Long-term efficacy of ofatumumab in patients with relapsing multiple sclerosis (2022) (0)
B Cells Responding to Viral Antigens Can Provoke a T Cell Response Against Myelin Antigens (P4.011) (2015) (0)
Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype (2015) (0)
Diagnosis of Multiple Sclerosis (2007) (0)
Fingolimod significantly lowers neurofilament light chain blood levels in RRMS patients as compared to interferon beta-1a or placebo (P6.376) (2017) (0)
Delayed Signs of Early Disability Progression After 8.5 Years of Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis (S46.003) (2023) (0)
Effects of a new computerised working memory training in patients with multiple sclerosis (2007) (0)
Syndrome of inappropriate antidiuretic hormone secretion and hypothalamic hypocortisolism in neuromyelitis optica (2021) (0)
Erratum: J Neurol (2002) 249: 1088–1097 (2002) (0)
White matter lesion filling improves the accuracy of cortical thickness measurements in multiple sclerosis patients: a longitudinal study (2014) (0)
Vitamin D As Predictor Of Multiple Sclerosis Activity And Progression In Patients With CIS Treated Early With Interferon beta-1b (P5.016) (2014) (0)
Neurofilament Light Chain Levels and Disease Activity During Long-Term Treatment of Relapsing Multiple Sclerosis with the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib (P1-3.011) (2023) (0)
199 Changes in natalizumab exposure and PML incidence over time (2019) (0)
Natalizumab reduces loss of visual function in patients with relapsing multiple sclerosis (2006) (0)
Axonal damage explains part of and extends beyond the diffuse pathology evidenced by T1 mapping in normal-appearing white matter of multiple sclerosis patients (2019) (0)
031 Long-term efficacy of ocrelizumab in primary progressive multiple sclerosis: 6.5-study years (2022) (0)
A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression (2018) (0)
Response to “Letter to the Editor” by Houff et al. (2008) (0)
177 Updated safety analysis of ocrelizumab in multiple sclerosis (2019) (0)
Inflammatory Diseases of the Central and Peripheral Nervous System in Patients with Systemic Lupus Erythematosus: Autoantibody Findings and Clinical Phenotype (P6.108) (2016) (0)
BRAIN VOLUME CHANGE AND DISABILITY IN FINGOLIMOD TRIALS (2014) (0)
Development of Chronic Black Holes (CBH) Predicts Long Term Disability: Post-hoc Analysis of Magnetic Resonance Imaging (MRI) Data in the PRISMS Study (P7.251) (2015) (0)
Prediction of gadolinium enhancement status on MRI at baseline of multiple sclerosis trials (2004) (0)
[What is your diagnosis? HTLV-I myelopathy]. (1991) (0)
Serum Glial Fibrillary Acidic Protein compared with Neurofilament Light Chain as Biomarker for Multiple Sclerosis Disease Progression (P5-3.016) (2023) (0)
Reply (2011) (0)
PO128 Infusion-related reactions with ocrelizumab in rms and ppms (2017) (0)
Cardiac safety and tolerability of fingolimod in relapsing MS patients from the FIRST study who transitioned into the LONGTERMS study (2015) (0)
Long-Term Disease Control with Fingolimod in RRMS Patients With Active Disease (P6.388) (2018) (0)
Late Breaking News (1976) (0)
Assessment of Baseline Characteristics, Treatment Efficacy, and Serious Adverse Events among Natalizumab-Treated MS Patients without Prior Treatment (P06.172) (2012) (0)
Detection of normal appearing white matter abnormality in MS – A comparative study slow diffusion component change patterns in relapsing-remitting MS and subcortical vascular changes (2006) (0)
Functional connectivity changes of the motor network in patients with multiple sclerosis: a multicentre fMRI study (2009) (0)
Treatment with interferon reduces the appearance of lesions in clinically relevant white matter tracts in patients with clinically isolated syndrome (2016) (0)
Predictors of freedom from detectable disease activity in patients with clinically isolated syndrome treated with interferon beta-1b in the BENEFIT trial (2014) (0)
0488 The MSBase global web registry: joining independent local patient databases for multi-centre research (2005) (0)
Abstracts from PACTRIMS (2013) (0)
Results of DECIDE: DAC HYP Superior to IFN- -1a for RRMS (2014) (0)
Secondary Progressive Multiple Sclerosis (2022) (0)
Subcutaneous Interferon Beta-1a Decreases the Evolution of Gadolinium-Enhancing Lesions Into Chronic Black Holes in Relapsing Multiple Sclerosis (P7.240) (2014) (0)
Long-term Effect of Ofatumumab Treatment on Serum Neurofilament Light Chain Levels and NEDA-3 Status in Patients With RMS: Results From ASCLEPIOS I/II and ALITHIOS (P6-3.013) (2023) (0)
Early therapy with IFNB-1b started at the first event suggestive of MS reduces the evolution of persistent T1 hypointensities on brain MRI (2012) (0)
Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis (2023) (0)
Comments on "Evidence for Acute Neurotoxicity After Chemotherapy" Reply (2011) (0)
143 Effect of siponimod on disability progression measured by ambulation score: post hoc analysis of EXPAND (2022) (0)
SUSTAINED LOW RATE BRAIN VOLUME LOSS IN LONG TERM FINGOLIMOD TREATMENT (2015) (0)
Exploring the Relationship Between Serum GDF-15 and Disease Stability in Patients with a First Clinical Demyelinating Event Treated with Subcutaneous Interferon Β-1a Or Placebo in the REFLEX Study (2023) (0)
Tentative and Confirmed Disability Progression in MS Clinical Trials (P2.115) (2016) (0)
OPL114 The effects of baseline disease activity on magnetic resonance imaging (MRI) outcomes in the AFFIRM study (2005) (0)
The integration of clinical and paraclinical measures (1997) (0)
Syrinx like formations as a rare feature of spinal cord involvement in multiple sclerosis (2007) (0)
Effect of Two Dosing Frequencies of Subcutaneous Interferon (scIFN) β-1a on Conversion to Multiple Sclerosis (MS) in Patients with a First Clinical Demyelinating Event (FCDE): 5-year Results of Phase III, Double-blind, Multicenter Trials (REFLEX/REFLEXION) (P7.206) (2015) (0)
Slowing of cerebral atrophy after year 1 in a placebo-controlled trial of interferon beta 1b in secondary progressive multiple sclerosis (2007) (0)
085 Clinical outcomes were better for relapsing-remitting multiple sclerosis (RRMS) patients who remained on natalizumab compared to those who switched to oral or injectable therapies after 2 years in the tysabri® observational program (TOP) (2018) (0)
Transition to non-active secondary progressive multiple sclerosis (SPMS) after up to 9.5 years of natalizumab treatment in the real-world TYSABRI Observational Program (TOP) (2802) (2020) (0)
Abnormal connectivity inside the motor network in patients with multiple sclerosis: a multicentre fMRI study (2008) (0)
Secondary Progressive Multiple Sclerosis A Review of Clinical Characteristics, De ﬁ nition, Prognostic Tools, and Disease-Modifying Therapies (0)
Creating accurate reference segmentations of deep GM structures in MS patients by fast semi-automated outlining (2018) (0)
Safety and Tolerability of BG-12 (Dimethyl Fumarate) in Patients with Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of Phase 2 and 3 Placebo-Controlled Studies (S30.003) (2013) (0)
Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis (2023) (0)
Efficacy of Subcutaneous Interferon Β-1a in Patients with a First Clinical Demyelinating Event in REFLEX is Maintained After Application of the 2017 McDonald Criteria (2020) (0)
OCRELIZUMAB VS INTERFERON β-1A IN RELAPSING MS: TWO STUDIES (2016) (0)
Cortical laminar assessment of T1 and T2*in the cerebellum of MS patients and controls at 7T MRI (2019) (0)
Deep learning analysis applied to multi-parametric advanced MRI shows higher myelin content and neurite density in juxtacortical lesions compared to periventricular lesions (2019) (0)
4-Year Follow-up of Delayed-Release Dimethyl Fumarate Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS): Integrated Magnetic Resonance Imaging (MRI) Outcomes From DEFINE, CONFIRM, and the ENDORSE Extension Study (P3.160) (2014) (0)
[Immunosuppression and -modulation in neurologic diseases. Assessment of status and recent developments]. (1989) (0)
EXERCISE IMPROVES SIT-TO-STAND FUNCTION IN PEOPLE WITH MULTIPLE SCLEROSIS (2012) (0)
Regional gray matter volumes changes in relapsing-remitting and secondary progressive multiple sclerosis - a longitudinal comparative voxel-based morphometry study (2010) (0)
Longer duration of natalizumab exposure may lessen return of disease activity following a switch from natalizumab to an oral therapy: modelling real-world data from relapsing-remitting multiple sclerosis (RRMS) patients in the TYSABRI® Observational Program (TOP) (P6.379) (2018) (0)
Corrigendum to 'Effects of Delayed-release Dimethyl Fumarate (DMF) on Health-related Quality of Life in Patients With Relapsing-remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies: [Clinical Therapeutics 36 (2014) 1958-1971]. (2018) (0)
Correction: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis (2011) (0)
Gadolinium-DTPA Enhanced MRI in Multiple Sclerosis: A New Method to Monitor Disease Activity and Treatment Efficacy (1989) (0)
Clinical Correlations of Brain Lesion Location in Multiple Sclerosis: Voxel-Based Analysis of a Large Clinical Trial Dataset (2018) (0)
Magnetic Resonance Imaging in Isolated Optic Neuritis (1989) (0)
Does altered functional activation in MS patients reflect loss or presence of compensatory brain mechanisms (2001) (0)
Trial design and baseline data of the INFORMS (fingolimod in patients with primary progressive multiple sclerosis) study (2012) (0)
Two-Year Interim Analysis of Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Delayed-Release Dimethyl Fumarate in the ENDORSE Study (P4.178) (2014) (0)
Subject Index Vol. 30, 1990 (1990) (0)
Do patients with thalamic pain have a specific somatosensory phenotype? (P1.222) (2017) (0)
Anti-KIR4.1 antibodies do not differentiate multiple sclerosis patients from controls (P5.276) (2016) (0)
141 Cognitive processing speed predicts disease progression in SPMS: post hoc analysis from the EXPAND study (2022) (0)
Neurophysiological results Day 3 Day 19 Day 90 Normal Motor : Right cubital nerve (0)
Effect of Longer-term Ofatumumab Treatment on Disability Progression and Brain Volume Change (S16.009) (2023) (0)
Long Term Impact of Early Initiation of Interferon beta-1b after a First Clinical Event Suggestive of Multiple Sclerosis: Additional Relapse Rate, EDSS, and MSSS Analyses after 8 Years (P07.117) (2013) (0)
Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis (2023) (0)
Comparison of MS outcomes after Switching to Natalizumab versus staying on Interferon-beta or glatiramer (2016) (0)
Baseline Characteristics of Patients with Relapsing Multiple Sclerosis in ASCLEPIOS Phase 3 Trials of Ofatumumab Versus Teriflunomide (P3.2-096) (2019) (0)
[Early summer meningoencephalitis vaccination. The indications and a critical assessment of the neurological vaccination complications]. (1992) (0)
DACLIZUMAB HYP VS IM INTERFERON BETA-1A IN MS: NEDA RESULTS FROM DECIDE (2016) (0)
The effects of natalizumab monotherapy on multiple measures of disability progression in MS patients (2006) (0)
Muscle stiffness, gait instability, and liver cirrhosis in Wilson's disease (2020) (0)
Progression to disability milestones in multiple sclerosis with long-term natalizumab treatment (2016) (0)
Treating clinically isolated syndromes suggestive of MS – Authors' reply (2007) (0)
Overall Response Score: A Novel Disability Endpoint That Allows for the Integrated Assessment of Improvement and Worsening over Time in Patients with MS (P4.380) (2018) (0)
Effects of cognitive training in MS patients visualized by functional MRI (2002) (0)
Ofatumumab Reduces Disability Progression Independent of Relapse Activity in Patients with Relapsing Multiple Sclerosis (1845) (2020) (0)
Contents, Vol. 30, 1990 (1990) (0)
Serial gadolinium MRI and clinical correlation 1 year results of the European DSG trial (1995) (0)
Longitudinal changes of deep gray matter shape in multiple sclerosis (2022) (0)
Analysis of neutralising antibodies in the Betaferon (R) in newly emerging multiple sclerosis for initial treatment (BENEFIT) study (2006) (0)
[15+/-deoxyspergualin, hope for patients with multiple sclerosis?]. (1992) (0)
Effect of fingolimod versus interferon-beta1a on neda-4 (no evidence of disease activity or worsening) in the transforms study (2015) (0)
MULTIPLE SCLEROSIS TRIALS. AUTHOR'S REPLY (1999) (0)
[Adrenoleukodystrophy: the significance of peroxisomal disease in adult neurology]. (1990) (0)
Experimentally induced fatigue in MS patients (2004) (0)
MATTERS ARISING (1992) (0)
Combined chemotherapy of inoperable and operable malignant gliomas (1984) (0)
Improvement in Cognitive Processing Speed With Ofatumumab in Patients With Relapsing Multiple Sclerosis (P6-3.005) (2023) (0)
Disability accrual in primary and secondary progressive multiple sclerosis (2023) (0)
Subject Index Vol. 40, 2007 (2007) (0)
Cognitive impairment in relapsing-remitting multiple sclerosis ( RRMS ) : psychometric properties of the Brief Repeatable Battery of Neuropsychological tests ( BRB-N ) (2014) (0)
Investigating the Effect of Teriflunomide on Brain Volume Loss in the Phase 3 TOPIC Study (2019) (0)
Long-term safety of interferon beta-1b (IFNB-1b) treatment in early multiple sclerosis ( MS): The 11-year follow-up of BENEFIT (BENEFIT-11) (2016) (0)
The Timed 25-foot Walk Test as an Alternative to EDSS Score for Evaluating ‘No Evidence of Disease of Activity’ (NEDA-4) Status in Patients with RRMS (P2.143) (2016) (0)
Evaluation of the Long-term Treatment Effect of Teriflunomide on Cognitive Outcomes and Association With Brain Volume Change: Data From TEMSO and its Extension Study (P6.372) (2018) (0)
MRI and PET correlates of cognitive dysfunction (1997) (0)
Neurorehabilitation in Multiple Sclerosis : does functional MRI allow inferences about effectiveness? (2003) (0)
Magnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study (2015) (0)
Long-term Prognosis of Disease Evolution and Evidence for Sustained Fingolimod Treatment Effect by Blood Neurofilament Light in RRMS Patients (S24.004) (2018) (0)
Safety and Tolerability of Siponimod in Patients with Secondary Progressive Multiple Sclerosis (S33.007) (2017) (0)
P30.35 Multimodal visual, motor and somatosensory evoked potentials as markers of clinical disability in primary progressive multiple sclerosis (2006) (0)
[Results of the 2d study on the structure of neurologic inpatient facilities in West Germany]. (1986) (0)
Effect of Two Dosing Frequencies of Subcutaneous Interferon (scIFN) β-1a on MRI Lesion and Brain Volume Changes in Patients with a First Clinical Demyelinating Event (FCDE): 5-year Results of Phase III REFLEX Study Extension (REFLEXION) (P7.250) (2015) (0)
Impact of Gadolinium-enhancing (GD+) Lesions on No Evidence of Disease Activity (NEDA) Status in Subcutaneous Interferon Beta-1a (SC IFNβ-1a)-treated Patients (2018) (0)
Effects of Ozanimod on Cognitive Processing Speed: Findings From the Phase 3 SUNBEAM and DAYBREAK Extension Trials (P6-3.001) (2023) (0)
A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients. (2023) (0)
Benefit 11: Long-term follow-up study of patients with clinically isolated syndrome treated with interferon beta-1b (2013) (0)
067 Neurofilament light chain concentration predicts risk of relapse in participants with relapsing multiple sclerosis in phase 3 ozanimod trials (2021) (0)
Contents Vol. 40, 2007 (2007) (0)
The immunogenicity of natalizumab in patients with multiple sclerosis: Results from the AFFIRM study (2007) (0)
Serum metabolic profile in early multiple sclerosis as predictor of long-term disease progression in BENEFIT (P5-3.013) (2023) (0)
Magnetization Transfer Ratio Imaging in Multiple Sclerosis: a Comparison of 3D Balanced Steady-State Free Precession and 2D Gradient Echo Sequences in Clinical Studies (2008) (0)
The spatio-temporal relationship between concurrent lesion and brain atrophy changes in early multiple sclerosis: A post-hoc analysis of the REFLEXION study (2023) (0)
Dimethylfumarat (BG-12) (2013) (0)
Postmortem quantitative MRI disentangles histological lesion types in multiple sclerosis. (2022) (0)
Intrasubject Longitudinal Change in Topographic Visual Evoked Potentials in Patients with Relapsing Multiple Sclerosis (P6.308) (2016) (0)
IN29-TU-03 Correlating pathology and imaging abnormalities (2009) (0)
Lesional Magnetization Transfer Ratio — a Feasible Outcome for Remyelinating Treatment Trials in MS (2010) (0)
Cognitive dysfunction in patients with early relapsing-remitting multiple sclerosis, Expanded Disability Status Scale (2008) (0)
043 Efficacy of siponimod in secondary progressive multiple sclerosis with active disease: EXPAND study subgroup analysis (2022) (0)
P60 Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis (2019) (0)
Reduced resting-state connectivity in the brain ' s default mode network in patients with mild forms of relapsing-remitting MS (2008) (0)
Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis (2023) (0)
Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab (2023) (0)
[Sclerotic plaques and hepatitis B vaccination in adults: the situation in 2004. Response]. (2005) (0)
Confirmed disability progression as a marker of permanent disability in multiple sclerosis (2022) (0)
Longitudinal assessment of cervical spinal cord compartments in multiple sclerosis. (2023) (0)
Data from: Effect of dimethyl fumarate on lymphocytes in RRMS: implications for clinical practice (2019) (0)
Alemtuzumab Treatment Reduces Serum Neurofilament to Levels Comparable With Healthy Controls More Effectively Than SC IFNb-1a: CARE-MS I (2019) (0)
, Nicole matter lesion volume in MS 3 D GRASE arterial spin labelling reveals an inverse correlation of cortical perfusion with the white (2012) (0)
Five-Year Safety of Ofatumumab in People Living With Relapsing Multiple Sclerosis (P8-3.004) (2023) (0)
Efficacy of Early Ofatumumab vs Late Switch From Teriflunomide: Subgroup Analysis of the ALITHIOS Open-label Extension Study by Previous Disease-Modifying Therapy Exposure and Age (P6-3.016) (2023) (0)
The effect of natalizumab on brain atrophy in patients with relapsing multiple sclerosis: 2-year results from the AFFIRM study (2005) (0)
Disability Progression in Multiple Sclerosis Patients Treated with Natalizumab in the Long-term STRATA Study (P3.163) (2014) (0)
Magnhild sclerosis : exploratory analyses from the PRISMS long-term follow-up study remitting multiple − Impact of exposure to interferon beta-1 a on outcomes in patients with relapsing (2011) (0)
[What is your diagnosis? Extrameatal space-occupying acoustic neuroma]. (1992) (0)
Incidence Of Macular Edema (ME) In Fingolimod (FTY720) Multiple Sclerosis (MS) Clinical Program (2012) (0)
Improved Characterization of Visual Evoked Potentials in Multiple Sclerosis by Topographic Analysis (2013) (0)
Monitoring tools in MS : quantitative, semi-quantitative and ordinal evoked potential scores (2016) (0)
Effect of Early Versus Delayed Subcutaneous Interferon (scIFN) β-1a to Achieve No Evidence of Disease Activity (NEDA) in Patients with Clinically Isolated Syndrome (CIS): A Post-hoc Analysis of REFLEXION (P3.111) (2016) (0)
Validation of the clinical classification scheme using MRI in the BENEFIT Study (2005) (0)
Reporting of subgroup analyses from clinical trials – Author's reply (2012) (0)
MAGNETIZATION TRANSFER RATIO OF NORMAL APPEARING SUBCORTICAL BRAIN STRUCTURES IN MS PATIENTS MEASURED WITH BALANCED STEADY STATE FREE PRECESSION IMAGING (2012) (0)
Improving Accuracy of Brainstem MRI Volumetry: Effects of Age and Sex, and Normalization Strategies (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ludwig Kappos?

Ludwig Kappos is affiliated with the following schools: